

Table S1. GDM case and control ascertainment criteria for GWAS contributing to trans-ancestry meta-regression.

Study acronym	Study name	PMID	Ascertainment		Ancestry group(s)
			Cases	Controls	
ALSPAC	Avon Longitudinal Study of Parents and Children	22507742	Clinical diagnosis noted in medical records or self-reported and no previous self-reported diabetes	Absence of clinical diagnosis noted in medical records or self-reported diabetes during or before the pregnancy	EUR
AM	ANDIS-MDC	https://doi.org/10.1101/2020.09.29.20203935	Gestational diabetes diagnosis with no previous diabetes diagnosis	Healthy non-diabetic women	EUR
BIB	Born in Bradford	23064411	Modified WHO criteria applied to fasting and 2-hour postload glucose without previously recorded diabetes	Healthy women who did not have any record of diabetes during or before the pregnancy	EUR, SAS
BOTNIA	The Botnia Study	https://doi.org/10.1101/2020.09.29.20203935	Gestational diabetes diagnosis with no previous diabetes diagnosis	Healthy women who did not have any record of diabetes during the pregnancy	EUR
DECODE	deCODE Genetics	-	Diagnosis of gestational diabetes in medical records from The National University Hospital of Iceland 1997-2016, ICD10: O24.4 and O24.9).	Women recruited through different genetic research projects at deCODE, matched with the cases on age, and county of origin. Women with type 2 diabetes were excluded from the control group.	EUR
EGCUT	Estonian Biobank, University of Tartu	24518929	Gestational diabetes diagnosis with no previous diabetes diagnosis	Women without GDM diagnosis	EUR
ERF	Erasmus Rucphen Family Study	15054401	Gestational diabetes diagnosis with no previous diabetes diagnosis	Women without GDM diagnosis	EUR
ESTGDM	Estonian Gestational Diabetes Samples	29879500	All women performed fasting oral glucose tolerance test with 75g glucose between gestational weeks 23 to 31 weeks. GDM was diagnosed according to the IADPSG criteria.	All women performed fasting oral glucose tolerance test with 75g glucose between gestational weeks 23 to 31 weeks. Women who stayed normoglycemic were classified as non-GDM.	EUR
FINNGEDI	The Finnish Gestational Diabetes Study	32374401	GDM status based on 75 g OGTT at 12-16 weeks (high risk women) or at 24-28 weeks of gestation. Fasting plasma	Women without GDM diagnosis (normal OGTT at 24-28 weeks of gestation).	EUR

			glucose ≥ 5.3 mmol/l, 1-hour glucose ≥ 10.0 mmol/l or 2- hour glucose ≥ 8.6 mmol/l.		
GEN3G	Genetics of Glucose regulation in Gestation and Growth	26842272	All women performed a fasting 75g oral glucose tolerance test (OGTT) between 24 to 30 weeks of gestation. GDM was defined based on IADPSG criteria. Women also had a screening at 1 st trimester (A1c and/or GCT) to exclude pre-existing diabetes prior to pregnancy	All women performed a fasting 75g oral glucose tolerance test (OGTT) between 24 to 30 weeks of gestation. Women who did not meet the IADPSG criteria for GDM were classified as “normoglycemic” controls. Women also had a screening at 1 st trimester (A1c and/or GCT) to exclude pre-existing diabetes prior to pregnancy	EUR
GIFTS	Genomic and Lifestyle predictors of foetal outcome relevant to diabetes and obesity and their relevance to prevention strategies in South Asian peoples	31711436	GDM was diagnosed based on revised WHO 1999 guidelines. Women with a prior history of type 2 diabetes, or gestational diabetes or pregnancy induced hypertension were excluded.	Women without a GDM diagnosis that were recruited	SAS
HONGKONG	The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study conducted in the Hong Kong field centre	28279981	All pregnant women less than 31 weeks of gestation. GDM was diagnosed according to the World Health Organization 2013 criteria for women with either FPG ≥ 5.1 mmol/l, 1-hour glucose ≥ 10.0 mmol/l or 2- hour glucose ≥ 8.5 mmol/l during pregnancy	Healthy women who did not have any record of diabetes during the pregnancy	EAS
NFBC66	Northern Finland Birth Cohort 1966	-	Self-reported GDM (ever in their life) at 46yrs follow-up OR GDM diagnosis found in the birth register/Care Register for Health Care (registers up to 2012)	Self-reported (been pregnant but) never had GDM at 46yrs follow-up. Men, and subjects with no information on pregnancies nor GDM were excluded	EUR
NFBC86	Northern Finland Birth Cohort 1986	-	Cohort subjects who had abnormal OGTT or blood glucose curve during pregnancy	Cohort subjects who had no indications (glucosuria, prior gestational diabetes, macrosomia in current pregnancy, previous macrosomic infant (weight more than 4500g), BMI > 25 and maternal age > 40 yr) and did not take OGTT OR OGTT was normal. Cohort subjects who had pre-pregnancy DM OR information on	EUR

				indications and/or missing OGTT were excluded	
NU	Northwestern Feinburg School of Medicine	23903356	age<18 or > 40, multiple pregnancy, pregestational diabetes (type 1 or 2) or diabetes discovered at the first trimester, drugs and/or alcohol abuse, uncontrolled endocrine disease, renal failure, or other major medical conditions that would affect glucose regulation	Healthy women who did not have any record of diabetes during the pregnancy	AFR, EAS, EUR, HIS
PREDO	The Prediction and Prevention of Preeclampsia and Intrauterine Growth Restriction study	27639277	Gestational diabetes diagnose based on 75 g glucose tolerance test. Fasting plasma glucose ≥ 5.2 mmol/l, 1-hour glucose ≥ 10.0 mmol/l or 2- hour glucose ≥ 8.7 mmol/l.	Women with no record of gestational diabetes, type 1 or type 2 DM. Control women may have other pregnancy disorders	EUR
SNUH	Seoul National University Hospital	22233651	The GDM case group was selected from a hospital-based cohort enrolled between January 1996 and February 2003 from Cheil General Hospital. A 50-g 1-h glucose challenge test was performed during 24–28 weeks' gestation in order to screen for GDM, and a glucose level of ≥ 7.2 mmol/L was considered positive and warranted a diagnostic 100-g oral glucose tolerance test. Glucose and insulin concentrations were measured at 0, 1, 2, and 3 h of the glucose challenge. GDM was diagnosed according to the criteria of the Third International Workshop Conference on GDM. The thresholds for the diagnosis of GDM were as follows: fasting ≥ 5.8 mmol/L, 1 h ≥ 10.6 mmol/L, 2 h ≥ 9.2 mmol/L, and 3 h ≥ 8.1 mmol/L.	Nondiabetic control subjects were selected from two population-based cohort studies, the rural Ansung and the urban Ansan cohorts. The two cohorts comprised the Korean Genome Epidemiology Study and included 5,018 and 5,020 subjects, respectively. Only women were eligible for enrollment. From the Korean Genome Epidemiology Study subjects, we included 1,242 nondiabetic women according to the following criteria: age ≥ 50 years, no previous history of type 2 diabetes, no first-degree relatives with type 2 diabetes, fasting plasma glucose level < 5.6 mmol/L, and HbA1c $< 6.0\%$. Information on parity and glucose tolerance status during pregnancy was not available for the control group.	EAS
STORK	Project STORK	22108914	Diagnosis based on WHO99 criteria	Women without GDM diagnosis	EUR

STORKG	STORK Groruddalen	21062840	Universal screening of GDM with 75 g oral glucose tolerance test in pregnancy week 28. GDM diagnosed according to WHO99 criteria. Normoglycemic at inclusion in pregnancy week 15.	Normal fasting glucose and 2-hour glucose after 75 g oral glucose tolerance test in pregnancy week 28.	EUR
UKBB	UK Biobank	25826379, 30305743	- O24.4 (Diabetes mellitus arising in pregnancy) or O24.9 (Diabetes mellitus in pregnancy, unspecified) diagnosis in the Hospital inpatient admissions data - GDM self-report diagnosis (code 1221, field 20002 "Non-cancer illness code, self-reported") - GDM self-report diagnosis using field 4041 "Did you only have diabetes during pregnancy?" - E10 - E14 diagnosis in the hospital inpatient admission data, followed by an obstetrical diagnosis within 0–120 days or if it preceded an obstetrical diagnosis by 0–180 days	Women with at least one pregnancy (number of births field 2734) and without GDM or T2D diagnoses	EUR
VIVA	Project Viva	24639442	We defined gestational glucose tolerance in categories according to the results of routine prenatal screening. Clinicians screened all pregnant women at 26–28 weeks of gestation with a non-fasting oral glucose challenge test, in which venous blood was sampled 1 h after a 50 g oral glucose load. If the blood glucose exceeded 140 mg/dl, the clinician referred the woman for a fasting 3-h 100 g oral glucose tolerance test (OGTT). Abnormal OGTT results were a blood glucose >95 mg/dl fasting, >180 mg/dl at 1 h, >155 mg/dl at 2 h, or >140 mg/dl at 3 h. Women with two or more abnormal values on the OGTT	Women without GDM. The control group included women with GIGT, IH, and normal glucose as controls.	EUR

			were diagnosed with GDM. We further classified those with one abnormal value on the OGTT as having gestational impaired glucose tolerance (GIGT), those with an abnormal glucose challenge test but a normal OGTT as having isolated hyperglycemia (IH) and the remaining women as having normal glucose tolerance.		
--	--	--	---	--	--

Table S2. Sample characteristics of GWAS contributing to trans-ancestry meta-regression.

Study acronym	Population group	Country of origin	Genotyping array(s)	Effective sample size	GDM status	Sample size	Age (years) mean (SD)	BMI (kg/m ²) mean (SD)
African ancestry								
NU (AFR)	African American	USA	Illumina Human1M-Duov3 B SNP array	333.2	Case	91	29.4 (6.4)	32.1 (7.5)
					Control	985	24.9 (5.3)	27.2 (5.7)
East Asian ancestry								
HONGKONG	Chinese	Hong Kong	Illumina InfiniumOmniZhongHua-8 v1.3 BeadChip	500.1	Case	148	33.1 (4.3)	21.7 (3.1)
					Control	805	30.9 (4.6)	20.8 (2.8)
NU (EAS)	Thai	Thai	Illumina HumanOmni1-Quad v1-0 B SNP array	791.9	Case	251	29.4 (5.7)	26.6 (3.9)
					Control	937	27.3 (5.4)	25.4 (3.5)
SNUH	Korean	South Korea	Affymetrix Genome-Wide Human Single Nucleotide Polymorphism (SNP) Array 5.0	1359.7	Case	468	31.5 (4.0)	23.3 (3.2)
					Control	1,242	59.1 (5.6)	24.6 (3.2)
European ancestry								
ALSPAC	British	UK	Illumina human660W-quad array	257.5	Case	65	28.6 (5.2)	25.9 (6.3)
					Control	6,803	27.9 (4.7)	22.9 (3.7)
AM	Swedish	Sweden	Illumina InfiniumCoreExome-24v1-1	1019.2	Case	305	-	-
					Control	1,548	-	-
BIB (EUR)	British	UK	Illumina HumanCoreExome12v1.0, HumanCoreExome12v1.1, HumanCoreExome24v1.0	580.7	Case	153	30.2 (5.5)	29.3 (6.8)
					Control	2,837	26.5 (6.0)	26.7 (6.0)
BOTNIA	Finnish	Finland	Illumina HumanOmniExpress-12v1-1	250.2	Case	69	-	-
					Control	670	-	-
DECODE	Icelandic	Iceland	various Illumina SNP arrays	2980.4	Case	750	32.4 (5.5)	30.7 (6.8)
					Control	114,000	-	25.6 (4.9)
EGCUT	Estonian/Russian	Estonia	Illumina Global Screening Array, Illumina OmniExpress, Illumina HumanHap 370CNV, Illumina CoreExomeChip	1017.1	Case	257	27.7 (6.1)	24.7 (4.7)
					Control	23,874	43.9 (16.6)	25.8 (5.3)
ERF	Dutch	The Netherlands	Illumina 318K, Illumina 370K and Affymetrix 250K	188.4	Case	49	49.2 (13.2)	28.5 (5.2)
					Control	1,222	50.9 (12.7)	27.0 (5.0)
ESTGDM	Estonian/Russian	Estonia	Illumina Global Screening Array	163.7	Case	52	32.2 (5.3)	26.8 (6.0)-
					Control	192	30.0 (5.4)	25.0(4.7)
FINNGEDI	Finnish	Finland	Infinium Omni2.5-8 BeadChip	529.2	Case	298	32.5 (5.3)	27.9 (6.1)
					Control	238	31.5 (5.2)	25.6 (4.8)
GEN3G	Canadian	Canada	Illumina Infinium Expanded Multi-Ethnic Genotyping Array (MEGA EX)	162.0	Case	44	29.7 (5.9)	28.6 (7.3)
					Control	511	28.1 (4.1)	25.5 (5.6)
NFBC66	Finnish	Finland	Illumina HumanCNV370DUO Analysis BeadChip	782.7	Case	220	-	28.9 (6.2)
					Control	1,769	-	26.3 (5.1)
NFBC86	Finnish	Finland	Human Omni Express Exome 8v1.2	106.8	Case	27	29.3 (6.2)	23.8 (4.4)
					Control	2,441	27.4 (5.0)	27.4 (5.0)

NU (EUR)	European American	USA	Illumina Human 610 Quad v1 B SNP array	589.5	Case	168	32.6 (4.9)	31.0 (5.8)
					Control	1,200	31.1 (5.3)	28.0 (4.5)
PREDO	Finnish	Finland	Illumina Global Screening Array	653.9	Case	213	32.8 (5.6)	30.7 (6.7)
					Control	703	31.9 (5.8)	26.5 (6.1)
STORK	Norwegian	Norway	Illumina Infinium CoreExome chip	39.2	Case	10	31.3 (3.9)	27.6 (3.3)
					Control	497	31.7 (4.4)	23.4 (3.7)
STORKG	European	Norway	Illumina Infinium CoreExome chip	130.4	Case	37	30.9 (4.5)	24.5 (4.7)
					Control	275	31.3 (4.9)	25.9 (5.1)
UKBB	British	UK	UK Biobank Axiom Array and UK BiLEVE Axiom Array	4117.0	Case	1,035	52.4 (8.3)	29.1 (6.2)
					Control	185,550	57.1 (7.8)	26.9 (4.9)
VIVA	American	USA	Illumina Infinium Expanded Multi-Ethnic Genotyping Array (MEGA EX)	103.1	Case	27	33.2 (4.6)	27.2 (6.5)
					Control	572	33.3 (4.4)	24.1 (4.6)
Hispanic/Latino ancestry								
NU (HIS)	Hispanic American	USA	Illumina Human1M-Duov3 B SNP array	543.3	Case	174	30.8 (5.5)	33.1 (6.4)
					Control	619	28.3 (5.3)	29.1 (4.9)
South Asian ancestry								
BIB (SAS)	Pakistani British	UK	Illumina HumanCoreExome12v1.0, HumanCoreExome12v1.1, HumanCoreExome24v1.0	1437.6	Case	405	30.7 (5.5)	28.4 (6.1)
					Control	3,192	27.5 (5.0)	25.5 (5.3)
GIFTS (1)	Bangladeshi	UK	Illumina Global Screening Array	125.8	Case	41	20.0 (2.6)	21.5 (2.6)
					Control	135	20.3 (3.0)	20.5 (3.4)
GIFTS (2)	Bangladeshi	Bangladesh	Illumina Global Screening Array	37.1	Case	11	23.1 (4.1)	23.6 (4.0)
					Control	59	22.5 (4.3)	21.9 (3.9)
GIFTS (3)	Bangladeshi	Bangladesh	Illumina Global Screening Array	354.4	Case	116	30.4 (5.7)	27.2 (4.0)
					Control	375	29.1 (5.3)	25.6 (4.5)

Table S3. Study-level quality control, pre-phasing, imputation and association analysis of GWAS contributing to trans-ancestry meta-regression.

Study acronym	Sample QC	SNV QC		Imputation			Association analysis				
	Call rate	Call rate	HWE p -value	Reference panel	Software	QC	QC+ SNVs	Relatedness and structure	Software	Covariates	λ_{GC}
African ancestry											
NU (AFR)	>95%	>95%	$>1 \times 10^{-4}$	1000G Phase 3	SHAPEIT2 + IMPUTEv2	info > 0.4	9,743,681	PC adjustment	EPACTS	-	1.01
East Asian ancestry											
HONGKONG	>98%	>99%	$>1 \times 10^{-4}$	1000G Phase 3	SHAPEIT2 (phasing) + Michigan imputation server	$r^2 > 0.4$	5,986,977	PC adjustment	EPACTS	-	1.01
NU (EAS)	>95%	>95%	$>1 \times 10^{-4}$	1000G Phase 3	SHAPEIT2 + IMPUTEv2	info > 0.4	6,698,571	PC adjustment	EPACTS	-	0.98
SNUH	>95%	>97%	$>1 \times 10^{-6}$	1000G Phase 3	Michigan imputation server	info > 0.4	5,751,976	Relateds removed, PC adjustment	EPACTS	-	1.02
European ancestry											
ALSPAC	>95%	>95%	$>1 \times 10^{-6}$	HRC	SHAPEIT2 + Sanger imputation server	$r^2 > 0.4$	5,723,169	PC adjustment	EPACTS	-	1.10
AM	>95%	>95%	$>1 \times 10^{-4}$	HRC	MINIMAC3	info > 0.4	7,201,324	PC adjustment	EPACTS	-	1.02
BIB (EUR)	$\geq 99.5\%$	$\geq 99.5\%$		Merged UK10K & 1000G Phase 3	EAGLE2 + Sanger Imputation Service		6,411,781	Mixed model	GCTA	-	1.02
BOTNIA	>95%	>95%	$>1 \times 10^{-4}$	1000G Phase 3	MINIMAC3	info > 0.4	5,825,870	PC adjustment	EPACTS	-	1.03
DECODE	>98%	>98%	$>1 \times 10^{-6}$	Icelandic reference panel	deCODE software	info > 0.4	8,356,461	LD-score regression intercept	deCODE software	-	1.01
EGCUT	>95%	>95%	$>1 \times 10^{-4}$	Estonian reference panel	SHAPEIT2 + IMPUTEv2	info > 0.4	6,695,203	Mixed model	EPACTS	-	1.04
ERF	>98%	>98%	$>1 \times 10^{-6}$	HRC	Michigan imputation server	$r^2 > 0.4$	4,459,573	Mixed model	Rvtest	Age	1.00
ESTGDM	>95%	>95%	$>1 \times 10^{-4}$	Estonian Reference panel	SHAPEIT2 + IMPUTEv2	info > 0.4	5,297,361	Mixed model	EPACTS	-	0.99
FINNGEDI	>95%	>95%	$>1 \times 10^{-4}$	HRC	SHAPEIT2 + PBWT	info > 0.4	7,646,486	Relateds removed, PC adjustment	PLINK	Age, BMI	1.05
GEN3G	>98%	>95%	$>1 \times 10^{-8}$	HRC	ShapeIT v2.r790 (phasing) + Michigan imputation server	info > 0.4	5,120,027	None	EPACTS	-	1.04
NFBC66	>95%	>95%	$>1 \times 10^{-4}$	HRC	IMPUTE2	info > 0.4	7,302,500	Relateds removed, PC adjustment	EPACTS	-	1.02
NFBC86	>95%	>95%	$>1 \times 10^{-4}$	HRC	IMPUTE2	info > 0.4	4,416,827	Relateds removed, PC adjustment	EPACTS	-	1.11
NU (EUR)	>95%	>95%	$>1 \times 10^{-4}$	HRC	SHAPEIT2 + IMPUTEv2	info > 0.4	7,041,417	PC adjustment	EPACTS	-	1.03
PREDO	>95%	>95%	$>1 \times 10^{-6}$	Finnish SiSu v2 imputation panel	Eagle v2.3 + IMPUTEv2	info > 0.4	6,910,245	PC adjustment	EPACTS	-	0.97
STORK	>95%	>95%	$>1 \times 10^{-6}$	1000G Phase 3	SHAPEIT2 + IMPUTEv2	info > 0.4	2,271,920	Relateds removed	SNPTEST	-	1.01
STORKG	>95%	>95%	$>1 \times 10^{-6}$	1000G Phase 3	SHAPEIT2 + IMPUTEv2	info > 0.4	4,607,366	Relateds removed	EPACTS	-	1.01

UKBB	>99%	>95%	>1x10 ⁻¹²	HRC and merged UK10K & 1000G Phase 3	IMPUTE4	info > 0.4	8,827,701	Mixed-model	BOLT-LMM	Age, genotyping array	1.02
VIVA	>95%	>98%	>1x10 ⁻⁶	HRC	ShapIT v2.r790 + Michigan imputation server	info > 0.4	4,395,851	PC adjustment	EPACTS	-	1.05
Hispanic/Latino ancestry											
NU (HIS)	>95%	>95%		1000G Phase 3	SHAPEIT2 + IMPUTEv2	info > 0.4	7,368,540	PC adjustment	EPACTS	-	1.02
South Asian ancestry											
BIB (SAS)	≥99.5%	≥99.5%		1000GPhase 3	EAGLE2 + Sanger Imputation Service	info > 0.4	7,517,804	Mixed model	GCTA	-	1.00
GIFTS (1)	>98%	>98%	>1x10 ⁻⁶	HRC	Michigan imputation server	info > 0.4	5,169,445	Relateds removed, PC adjustment	EPACTS	-	0.97
GIFTS (2)	>98%	>98%	>1x10 ⁻⁶	HRC	Michigan imputation server	info > 0.4	2,570,490	Relateds removed, PC adjustment	EPACTS	-	0.99
GIFTS (3)	>98%	>98%	>1x10 ⁻⁶	HRC	Michigan imputation server	info > 0.4	6,519,637	Relateds removed, PC adjustment	EPACTS	-	0.98

Table S6. Ancestry-specific GDM association summary statistics for lead SNVs at loci attaining genome-wide significance ($p < 5 \times 10^{-8}$) in the trans-ancestry meta-regression (MR-MEGA).

MTNR1B locus. Lead SNV: rs10830963. Risk/other allele: G/C

Ancestry	RAF	Association <i>p</i> -value	OR (95% CI)	Cases/Controls
African	0.046	0.94	1.04 (0.35-3.15)	91/985
East Asian	0.432	4.6×10^{-12}	1.51 (1.34-1.69)	867/2,984
European	0.264	2.3×10^{-42}	1.42 (1.35-1.49)	3,523/323,982
Hispanic/Latino	0.243	0.010	1.42 (1.09-1.85)	174/619
South Asian	0.403	0.0016	1.22 (1.08-1.39)	573/3,761

TCF7L2 locus. Lead SNV: rs7903146. Risk/other allele: T/C

Ancestry	RAF	Association <i>p</i> -value	OR (95% CI)	Cases/Controls
African	0.296	0.22	0.70 (0.39-1.24)	91/985
East Asian	0.034	0.14	1.24 (0.93-1.66)	867/2,984
European	0.284	8.7×10^{-16}	1.22 (1.17-1.29)	3,780/347,856
Hispanic/Latino	0.224	0.46	1.11 (0.84-1.48)	174/619
South Asian	0.313	0.0061	1.21 (1.06-1.39)	573/3,761

CDKAL1 locus. Lead SNV: rs9348441. Risk/other allele: A/T

Ancestry	RAF	Association <i>p</i> -value	OR (95% CI)	Cases/Controls
African	0.185	0.23	0.68 (0.36-1.28)	91/985
East Asian	0.401	6.8×10^{-14}	1.53 (1.37-1.72)	867/2,984
European	0.256	0.015	1.06 (1.01-1.12)	3,780/347,856
Hispanic/Latino	0.258	0.086	1.26 (0.97-1.65)	174/619
South Asian	0.261	0.082	1.13 (0.98-1.31)	573/3,761

CDKN2A-CDKN2B locus. Lead SNV: rs10811662. Risk/other allele: G/A

Ancestry	RAF	Association <i>p</i> -value	OR (95% CI)	Cases/Controls
African	0.885	0.15	0.58 (0.27-1.22)	91/985
East Asian	0.572	0.0017	1.20 (1.07-1.34)	867/2,984
European	0.824	2.4×10^{-7}	1.18 (1.11-1.25)	3,770/347,359
Hispanic/Latino	0.860	0.13	1.36 (0.92-2.02)	174/619
South Asian	0.547	0.16	0.90 (0.78-1.04)	562/3,702

HKDC1 locus. Lead SNV: rs9663238. Risk/other allele: G/A

Ancestry	RAF	Association <i>p</i> -value	OR (95% CI)	Cases/Controls
African	0.217	0.22	0.70 (0.40-1.23)	91/985
East Asian	0.264	0.0011	1.22 (1.08-1.38)	867/2,984
European	0.708	3.7×10^{-7}	1.14 (1.09-1.20)	3,557/346,656
Hispanic/Latino	0.531	0.77	1.04 (0.81-1.32)	174/619
South Asian	0.585	0.094	1.11 (0.98-1.26)	573/3,761

Table S5. Association of previously reported SNVs for T2D (180,834 cases and 1,159,055 controls of diverse ancestry from the DIAMANTE Consortium) on GDM in 5,485 cases and 347,856 controls of diverse ancestry.

Locus	Lead SNV	Chr	Position (bp, b37)	Alleles		T2D associatio n			GDM associatio n		
				T2D risk	Other						
<i>VWA5B1</i>	rs10916784	1	20,729,451	G	C	0.0342	0.0051	1.2E-11	0.0604	0.0204	1.8E-02
<i>MACF1</i>	rs3768301	1	39,870,793	T	C	0.0692	0.0063	6.2E-31	0.0157	0.0259	7.7E-02
<i>MAST2</i>	rs34444543	1	46,358,862	G	A	0.0349	0.0053	5.5E-13	0.0169	0.0216	6.8E-01
<i>FAF1</i>	rs12073283	1	51,219,188	C	G	0.0726	0.0086	6.7E-18	0.0845	0.0366	8.4E-02
<i>PGM1</i>	rs11576729	1	64,114,429	G	T	0.0487	0.0062	2.5E-17	0.0318	0.0247	1.5E-02
<i>PTGFRN</i>	rs1127215	1	117,532,790	C	T	0.0408	0.0050	3.9E-17	0.0176	0.0202	7.2E-01
<i>NOTCH2</i>	rs835576	1	120,455,586	C	T	0.0637	0.0081	2.8E-17	0.0741	0.0311	1.1E-01
<i>SEC16B</i>	rs539515	1	177,889,025	C	A	0.0536	0.0060	4.6E-20	0.0254	0.0250	4.2E-01
<i>ZNF281</i>	rs10919928	1	200,416,099	A	G	0.0339	0.0079	4.6E-09	N/A	N/A	N/A
<i>DSTYK</i>	rs6689629	1	204,539,291	A	G	0.0382	0.0059	2.4E-10	0.0024	0.0242	8.8E-01
<i>SRGAP2</i>	rs9429893	1	206,600,992	A	G	0.0316	0.0053	2.3E-09	0.0192	0.0201	3.3E-01
<i>PROX1</i>	rs340874	1	214,159,256	C	T	0.0562	0.0050	2.5E-33	0.0521	0.0199	9.5E-02
<i>LYPLAL1</i>	rs2820446	1	219,748,818	C	G	0.0444	0.0054	2.7E-18	-0.0028	0.0217	9.9E-01
<i>ABCB10</i>	rs348330	1	229,672,955	G	A	0.0451	0.0054	3.7E-18	0.0428	0.0211	2.0E-01
<i>TMEM18</i>	rs6548240	2	636,929	A	C	0.0673	0.0071	2.2E-25	0.0270	0.0275	5.2E-01
<i>DTNB</i>	rs55928417	2	25,533,568	G	T	0.0341	0.0053	4.0E-11	0.0217	0.0205	8.1E-01
<i>GCKR</i>	rs1260326	2	27,730,940	C	T	0.0625	0.0050	4.6E-38	0.1090	0.0207	6.8E-07
<i>THADA</i>	rs13414140	2	43,671,176	C	T	0.0881	0.0087	5.2E-31	0.0189	0.0352	3.1E-01
<i>SIX3-SIX2</i>	rs12712928	2	45,192,080	C	G	0.0091	0.0059	2.4E-14	-0.0343	0.0258	6.8E-01
<i>BNIP1</i>	rs17049712	2	58,961,136	T	C	0.0342	0.0056	2.3E-09	0.0094	0.0221	6.8E-01
<i>BCL11A</i>	rs243018	2	60,586,707	G	C	0.0595	0.0050	6.7E-35	0.0104	0.0200	4.3E-01
<i>CEP68</i>	rs6752053	2	65,666,674	T	C	0.0527	0.0054	4.1E-24	0.0147	0.0208	5.2E-01
<i>GLI2</i>	rs11677557	2	121,317,747	A	G	0.0527	0.0071	6.5E-15	0.0144	0.0293	9.6E-01
<i>CYTIP</i>	rs7594480	2	158,390,468	T	C	0.0760	0.0107	4.0E-12	0.1226	0.0471	7.6E-04
<i>RBSM1</i>	rs1020731	2	161,144,055	A	G	0.0307	0.0056	1.2E-09	0.0427	0.0242	1.9E-01
<i>KCNH7</i>	rs12614955	2	163,649,480	T	C	0.0323	0.0051	8.6E-10	0.0096	0.0224	3.3E-01
<i>GRB14</i>	rs10184004	2	165,508,389	C	T	0.0642	0.0056	5.2E-34	0.0206	0.0224	8.5E-01
<i>IKZF2</i>	rs16849467	2	213,818,731	T	C	0.0367	0.0062	4.8E-09	-0.0338	0.0241	5.0E-01

<i>IRS1</i>	rs2943648	2	227,100,490	G	A	0.0820	0.0058	3.6E-52	0.0361	0.0229	2.3E-01
<i>ATG16L1</i>	rs117809958	2	234,191,103	A	T	0.2114	0.0313	5.6E-12	N/A	N/A	N/A
<i>PPARG</i>	rs17036160	3	12,329,783	C	T	0.1059	0.0086	2.9E-38	0.0739	0.0312	1.8E-02
<i>UBE2E2</i>	rs13094957	3	23,457,080	T	C	0.0780	0.0059	5.2E-48	0.0592	0.0240	9.4E-02
<i>RBM6</i>	rs2624847	3	50,174,197	G	T	0.0333	0.0060	6.2E-11	0.0020	0.0237	6.7E-01
<i>CACNA2D3</i>	rs76263492	3	54,828,827	T	G	0.0918	0.0150	8.7E-10	N/A	N/A	N/A
<i>PXK</i>	rs12629058	3	58,338,809	T	C	0.0358	0.0057	3.5E-11	0.0425	0.0224	1.8E-01
<i>PSMD6-ADAMTS9</i>	rs704360	3	63,884,800	G	A	0.0676	0.0063	8.0E-33	0.0488	0.0280	5.1E-01
<i>ZBTB20</i>	rs1459513	3	114,960,798	C	A	0.0519	0.0069	9.6E-15	0.0243	0.0327	8.8E-01
<i>ADCY5</i>	rs11708067	3	123,065,778	A	G	0.0950	0.0071	3.4E-46	0.0815	0.0257	3.7E-02
<i>SLC12A8</i>	rs9873519	3	124,921,457	T	C	0.0375	0.0050	6.5E-14	0.0422	0.0202	2.2E-01
<i>MBNL1</i>	rs9877505	3	152,432,042	C	T	0.0378	0.0051	1.4E-13	0.0408	0.0212	3.6E-01
<i>SLC2A2</i>	rs8192675	3	170,724,883	T	C	0.0542	0.0055	3.5E-28	0.0297	0.0224	7.8E-03
<i>IGF2BP2</i>	rs7633675	3	185,510,613	G	T	0.1177	0.0053	5.8E-131	0.0996	0.0211	1.4E-06
<i>ST6GAL1</i>	rs3887925	3	186,665,645	T	C	0.0458	0.0049	3.8E-22	0.0387	0.0197	1.1E-01
<i>LPP</i>	rs4686471	3	187,740,899	C	T	0.0553	0.0062	2.9E-21	0.0350	0.0220	2.8E-01
<i>TFRC</i>	rs74289356	3	195,825,077	T	C	0.0463	0.0068	6.8E-12	0.0501	0.0322	3.0E-02
<i>PCGF3-MAEA</i>	rs730831	4	1,240,299	T	G	0.0917	0.0074	7.6E-41	0.0299	0.0243	8.4E-02
<i>WFS1</i>	rs9998835	4	6,293,237	G	C	0.0781	0.0058	3.1E-51	0.0450	0.0218	1.3E-01
<i>LCORL</i>	rs6855926	4	18,047,401	A	G	0.0354	0.0053	8.4E-12	0.0201	0.0216	7.3E-01
<i>GNPDA2</i>	rs13130484	4	45,175,691	T	C	0.0403	0.0051	1.3E-15	0.0215	0.0211	8.3E-01
<i>MOB1B</i>	rs7674402	4	71,835,822	A	G	0.0579	0.0078	1.2E-13	0.1003	0.0422	1.7E-01
<i>SCD5</i>	rs10471048	4	83,587,562	G	C	0.0310	0.0050	2.3E-11	0.0213	0.0206	6.2E-01
<i>NKX6-1-CDS1</i>	rs117624659	4	85,339,618	T	C	0.2135	0.0281	3.1E-14	N/A	N/A	N/A
<i>SMARCAD1</i>	rs6821438	4	95,091,911	A	G	0.0209	0.0050	2.5E-09	0.0326	0.0201	5.6E-01
<i>PPP3CA</i>	rs2659518	4	102,135,363	A	G	0.0383	0.0066	4.5E-09	0.0118	0.0314	6.5E-01
<i>SLC9B1</i>	rs223423	4	103,725,894	G	A	0.0210	0.0048	1.6E-09	0.0454	0.0198	6.2E-02
<i>TET2</i>	rs17035289	4	106,048,291	C	T	0.0410	0.0062	1.3E-12	0.0513	0.0253	2.8E-01
<i>TMEM154</i>	rs6813195	4	153,520,475	C	T	0.0622	0.0051	3.0E-36	0.0398	0.0217	2.9E-01
<i>PDGFC</i>	rs1425482	4	157,725,916	T	C	0.0287	0.0055	2.3E-11	0.0198	0.0226	8.9E-02
<i>ACSL1</i>	rs1996546	4	185,714,289	G	T	0.0621	0.0086	1.6E-13	0.0139	0.0319	1.5E-01
<i>ANKH</i>	rs6885132	5	14,768,092	C	G	0.0586	0.0064	9.5E-23	0.0260	0.0296	7.8E-01
<i>MRPS30</i>	rs6884702	5	44,682,589	G	A	0.0306	0.0049	6.0E-12	0.0130	0.0201	5.4E-01
<i>ITGA1</i>	rs17261179	5	51,791,225	T	C	0.0335	0.0050	6.9E-11	0.0309	0.0199	1.3E-01
<i>ARL15</i>	rs7736354	5	53,297,591	T	C	0.0444	0.0053	1.7E-20	0.0155	0.0223	9.1E-02

ANKRD55	rs465002	5	55,808,475	T	C	0.0740	0.0053	1.5E-51	0.0175	0.0216	1.8E-01
PIK3R1	rs57634870	5	67,716,793	G	T	0.0423	0.0060	6.0E-12	0.0464	0.0268	4.3E-01
POC5	rs2307111	5	75,003,678	T	C	0.0349	0.0050	1.3E-18	0.0331	0.0201	6.4E-02
ZBED3	rs7732130	5	76,435,004	G	A	0.0588	0.0064	6.0E-22	0.0859	0.0235	6.1E-03
DMGDH	rs10052346	5	78,472,599	G	T	0.0348	0.0050	5.7E-14	0.0230	0.0209	6.1E-01
SLC6A1-PAM	rs115505614	5	102,422,968	T	C	0.1625	0.0151	5.9E-29	0.0959	0.0525	3.7E-02
CEP120	rs4267865	5	122,704,342	G	T	0.0741	0.0105	9.7E-13	-0.0257	0.0470	5.2E-01
PHFI5	rs329122	5	133,864,599	A	G	0.0392	0.0049	6.0E-16	0.0131	0.0199	8.8E-01
NSD1	rs244708	5	176,589,585	G	A	0.0294	0.0050	3.8E-09	0.0119	0.0198	8.7E-02
SSR1-RREB1	rs9379084	6	7,231,843	G	A	0.0851	0.0079	6.1E-30	0.0594	0.0328	1.8E-01
CDKAL1	rs9348441	6	20,680,678	A	T	0.1541	0.0053	6.2E-235	0.1243	0.0219	1.6E-14
MHC region	rs879882	6	31,139,452	C	T	0.0507	0.0051	5.0E-26	0.0425	0.0208	2.3E-02
ZFAND3	rs34247110	6	39,282,371	A	G	0.0429	0.0049	3.4E-21	0.0403	0.0200	1.8E-01
LRFN2-KCNK16	rs34298980	6	40,409,243	T	C	0.0305	0.0053	4.1E-09	0.0309	0.0207	3.9E-01
VEGFA	rs6458354	6	43,814,190	C	T	0.0412	0.0059	1.3E-13	0.0487	0.0225	2.4E-01
TFAP2B	rs3798519	6	50,788,778	C	A	0.0563	0.0059	2.4E-22	0.0367	0.0243	5.0E-01
BEND3	rs1665901	6	107,433,400	A	T	0.0362	0.0054	6.1E-12	-0.0153	0.0213	8.2E-01
NUS1	rs72951506	6	118,011,723	C	T	0.0427	0.0065	9.9E-11	0.0400	0.0265	5.6E-01
CENPW-SOGA3	rs11759026	6	126,792,095	G	A	0.0684	0.0058	1.0E-36	0.0466	0.0239	9.8E-02
MED23	rs7739842	6	131,954,797	G	T	0.0374	0.0055	1.8E-13	0.0563	0.0233	1.2E-01
SLC35D3	rs6937795	6	137,291,281	A	C	0.0354	0.0049	5.3E-15	0.0471	0.0199	1.4E-01
REPS1	rs9376353	6	138,855,975	A	T	0.0306	0.0050	2.7E-10	0.0315	0.0202	4.7E-01
HIVEP2	rs6570526	6	143,058,692	G	C	0.0310	0.0049	8.2E-10	0.0162	0.0199	9.7E-03
RGS17	rs6932473	6	153,438,573	T	A	0.0365	0.0051	5.5E-13	0.0830	0.0207	1.6E-03
SLC22A3	rs539298	6	160,770,360	A	G	0.0386	0.0049	1.4E-15	0.0207	0.0200	8.5E-01
QKI	rs4709746	6	164,133,001	C	T	0.0475	0.0076	7.8E-10	0.0658	0.0313	2.1E-01
ETV1	rs12154701	7	13,887,008	A	C	0.0317	0.0049	1.4E-11	0.0426	0.0205	3.1E-01
DGKB	rs2215383	7	15,062,983	C	T	0.0657	0.0049	2.1E-44	0.0374	0.0200	8.0E-02
JAZF1	rs849133	7	28,192,280	C	T	0.0830	0.0051	2.3E-69	0.0625	0.0202	4.2E-02
CRHR2	rs917195	7	30,728,452	C	T	0.0486	0.0060	3.6E-16	0.0614	0.0244	8.1E-02
GCK	rs878521	7	44,255,643	A	G	0.0471	0.0055	2.2E-20	0.0690	0.0231	4.8E-02
GRB10	rs13236710	7	50,809,085	G	A	0.0491	0.0076	2.0E-11	0.0261	0.0309	3.4E-01
AUTS2	rs2533457	7	69,055,951	G	A	0.0409	0.0051	3.3E-19	0.0409	0.0204	2.4E-01
STEAP1	rs6978118	7	89,800,241	A	T	0.0335	0.0051	2.0E-14	0.0630	0.0203	2.8E-02
FBXL13-RELN	rs7781557	7	102,481,891	C	T	0.0527	0.0077	8.9E-12	0.0216	0.0285	1.9E-01

<i>GCC1-PAX4-LEP</i>	rs12669223	7	127,250,831	A	G	0.1912	0.0156	2.4E-39	N/A	N/A	N/A
<i>KLF14</i>	rs1562396	7	130,457,914	G	A	0.0385	0.0051	1.7E-16	0.0124	0.0215	7.3E-01
<i>BRAF</i>	rs11983228	7	140,631,823	C	G	0.0523	0.0083	5.0E-10	0.0816	0.0368	1.2E-01
<i>AOC1</i>	rs62492368	7	150,537,635	A	G	0.0315	0.0050	1.5E-10	0.0341	0.0212	3.5E-01
<i>MNX1</i>	rs10085650	7	156,993,413	T	C	0.0512	0.0050	3.9E-26	0.0507	0.0210	8.7E-02
<i>MSRA-XKR6</i>	rs4240673	8	10,787,612	T	C	0.0382	0.0058	1.1E-11	-0.0260	0.0220	1.1E-01
<i>LONRF1</i>	rs12680692	8	12,618,225	A	T	0.0324	0.0057	6.3E-10	0.0086	0.0224	2.0E-01
<i>LPL</i>	rs7819706	8	19,844,415	A	G	0.0510	0.0076	4.3E-13	0.0437	0.0330	4.8E-01
<i>KCNU1</i>	rs12680217	8	37,397,803	T	C	0.0498	0.0068	5.2E-15	0.0128	0.0321	8.5E-01
<i>ANK1</i>	rs508419	8	41,522,991	G	A	0.0823	0.0062	5.7E-47	0.0031	0.0242	9.1E-01
<i>GDAP1</i>	rs3780012	8	75,147,209	C	G	0.1320	0.0218	8.0E-10	N/A	N/A	N/A
<i>TP53INP1</i>	rs13257021	8	95,965,695	A	G	0.0428	0.0049	3.3E-20	0.0381	0.0200	3.2E-01
<i>TRPS1</i>	rs800909	8	116,497,173	T	C	0.0335	0.0053	8.1E-12	0.0034	0.0204	6.6E-01
<i>SLC30A8</i>	rs13266634	8	118,184,783	C	T	0.1124	0.0053	3.2E-115	0.0615	0.0210	2.9E-02
<i>PVT1</i>	rs4733612	8	129,569,999	G	A	0.0423	0.0063	2.4E-12	0.0717	0.0234	1.9E-03
<i>BOP1</i>	rs3890400	8	145,544,720	A	G	0.0458	0.0054	3.3E-18	0.0145	0.0211	1.7E-01
<i>GLIS3</i>	rs4237150	9	4,290,085	C	G	0.0566	0.0049	1.5E-36	0.0619	0.0204	8.1E-03
<i>HAUS6</i>	rs12380322	9	19,074,538	G	A	0.0315	0.0051	4.9E-10	0.0258	0.0205	3.7E-01
<i>CDKN2A-CDKN2B</i>	rs10811661	9	22,134,094	T	C	0.1694	0.0060	1.1E-201	0.1599	0.0261	4.6E-09
<i>LINGO2</i>	rs1412234	9	28,410,683	C	T	0.0342	0.0056	1.5E-11	0.0377	0.0217	7.0E-02
<i>UBAP2</i>	rs12001437	9	34,074,476	C	T	0.0315	0.0050	5.6E-11	0.0459	0.0204	1.5E-01
<i>TLE4</i>	rs13290396	9	81,914,978	C	T	0.0968	0.0094	1.4E-26	0.0368	0.0363	6.2E-01
<i>TLE1</i>	rs2796441	9	84,308,948	G	A	0.0645	0.0050	8.0E-42	0.0435	0.0201	1.6E-01
<i>ZNF169</i>	rs12345069	9	96,971,175	C	T	0.0382	0.0062	4.4E-10	0.0339	0.0236	4.8E-01
<i>PTCH1</i>	rs113154802	9	98,278,413	C	T	0.0511	0.0084	4.3E-12	0.0468	0.0340	7.2E-01
<i>STRBP</i>	rs2416899	9	126,015,103	T	G	0.0344	0.0063	3.5E-10	0.0296	0.0268	4.5E-01
<i>ABO</i>	rs505922	9	136,149,229	C	T	0.0457	0.0050	2.0E-21	0.0271	0.0214	2.7E-02
<i>GP5M1</i>	rs28429551	9	139,243,334	A	T	0.0842	0.0069	1.4E-39	0.0703	0.0261	1.8E-03
<i>CDC123-CAMK1D</i>	rs11257655	10	12,307,894	T	C	0.1025	0.0055	1.2E-91	0.0934	0.0227	8.2E-04
<i>MYO3A</i>	rs7923442	10	26,497,704	A	G	0.0354	0.0058	1.2E-09	0.0300	0.0254	8.5E-03
<i>JMJD1C</i>	rs41274074	10	64,974,380	G	C	0.0600	0.0092	3.1E-11	-0.0302	0.0472	8.3E-01
<i>VPS26A-NEUROG3</i>	rs177045	10	71,321,279	G	A	0.0450	0.0051	5.0E-23	0.0611	0.0211	4.3E-03
<i>ZNF503</i>	rs3012060	10	77,244,336	T	A	0.0450	0.0068	1.6E-12	0.0986	0.0294	1.8E-02
<i>ZMIZ1</i>	rs703980	10	80,943,841	G	A	0.0620	0.0049	8.7E-40	0.0507	0.0199	3.6E-02
<i>PTEN</i>	rs10887775	10	89,766,368	A	G	0.0388	0.0060	8.9E-11	0.0646	0.0265	4.0E-02

<i>HHEX-IDE</i>	rs10882101	10	94,462,427	T	C	0.1091	0.0050	1.8E-125	0.0717	0.0201	1.8E-03
<i>ARHGAP19-SLIT1</i>	rs10748694	10	99,056,190	A	T	0.0394	0.0050	5.1E-17	0.0357	0.0202	4.5E-01
<i>BBIP1</i>	rs7067540	10	112,621,837	C	T	0.0397	0.0053	1.1E-14	-0.0029	0.0221	9.5E-01
<i>TCF7L2</i>	rs7903146	10	114,758,349	T	C	0.2983	0.0062	0.0E+00	0.1961	0.0230	4.0E-16
<i>WDR11</i>	rs72631105	10	122,915,345	A	G	0.0504	0.0062	1.9E-18	0.0347	0.0243	5.9E-02
<i>PLEKHA1</i>	rs2421016	10	124,167,512	C	T	0.0425	0.0049	9.6E-23	0.0144	0.0199	5.7E-01
<i>DUSP8-INS-IGF2-KCNQ1</i>	rs2237897	11	2,858,546	C	T	0.2390	0.0081	5.5E-233	0.1721	0.0387	2.2E-04
<i>TRIM66</i>	rs10769936	11	8,654,528	C	T	0.0322	0.0051	6.9E-11	0.0388	0.0219	4.0E-01
<i>KCNJ11-ABCC8</i>	rs5215	11	17,408,630	C	T	0.0743	0.0050	1.3E-54	0.0560	0.0202	9.0E-03
<i>BDNF</i>	rs4923464	11	27,683,618	C	T	0.0317	0.0057	9.4E-10	0.0050	0.0243	7.7E-01
<i>QSER1</i>	rs145678014	11	32,927,778	G	T	0.0968	0.0166	5.7E-10	N/A	N/A	N/A
<i>HSD17B12</i>	rs6485462	11	43,816,200	C	T	0.0302	0.0053	4.8E-12	0.0576	0.0212	7.0E-02
<i>CRY2</i>	rs12419690	11	45,858,584	G	A	0.0343	0.0051	4.2E-11	0.0688	0.0201	8.9E-03
<i>FOLH1</i>	rs6485981	11	49,477,266	T	C	0.0410	0.0075	1.5E-09	-0.0024	0.0344	2.4E-01
<i>MAP3K11</i>	rs12789028	11	65,326,154	A	G	0.0544	0.0066	2.1E-17	0.0453	0.0272	4.8E-01
<i>TPCN2-CCND1</i>	rs3918298	11	69,463,273	G	A	0.1106	0.0138	3.3E-17	N/A	N/A	N/A
<i>CENTD2</i>	rs77464186	11	72,460,398	A	C	0.1039	0.0075	3.6E-49	0.1119	0.0271	6.0E-06
<i>C11orf30</i>	rs61894507	11	76,156,973	G	A	0.0352	0.0057	2.2E-10	-0.0102	0.0219	5.3E-01
<i>MTNR1B</i>	rs10830963	11	92,708,710	G	C	0.0840	0.0054	6.1E-66	0.3404	0.0218	4.3E-54
<i>ETS1</i>	rs11819995	11	128,389,391	T	C	0.0445	0.0059	2.5E-14	0.0379	0.0246	1.9E-01
<i>CCND2</i>	rs76895963	12	4,384,844	T	G	0.4575	0.0280	3.7E-71	N/A	N/A	N/A
<i>CDKN1B</i>	rs2066827	12	12,871,099	G	T	0.0467	0.0071	7.1E-11	0.0477	0.0258	1.4E-01
<i>ITPR2</i>	rs10842708	12	26,474,867	G	A	0.0385	0.0055	5.5E-14	-0.0035	0.0222	9.1E-01
<i>KLHDC5</i>	rs12578595	12	27,964,996	C	T	0.0663	0.0058	7.8E-33	0.0566	0.0247	1.5E-01
<i>FAM60A</i>	rs78345706	12	31,417,019	A	G	0.1157	0.0116	1.2E-24	N/A	N/A	N/A
<i>PKP2-SYT10</i>	rs6488140	12	33,370,406	A	G	0.0354	0.0060	9.1E-12	-0.0377	0.0269	1.1E-01
<i>FAIM2</i>	rs7132908	12	50,263,148	A	G	0.0319	0.0053	6.5E-10	0.0532	0.0207	7.5E-02
<i>HMGGA2</i>	rs2583930	12	66,246,181	G	A	0.0708	0.0059	5.1E-38	0.0444	0.0256	1.4E-01
<i>TSPAN8</i>	rs7313668	12	71,449,521	T	G	0.0413	0.0051	2.7E-17	0.0266	0.0204	6.2E-01
<i>RMST</i>	rs7972074	12	97,851,611	C	T	0.0347	0.0058	1.1E-10	0.0327	0.0268	7.0E-01
<i>WSCD2</i>	rs1426371	12	108,629,780	G	A	0.0479	0.0055	9.7E-19	0.0140	0.0227	6.4E-01
<i>ALDH2-BRAP</i>	rs3782886	12	112,110,489	T	C	0.0597	0.0116	1.1E-13	N/A	N/A	N/A
<i>PTPN11</i>	rs77753011	12	113,117,897	G	T	0.0769	0.0137	4.0E-15	N/A	N/A	N/A
<i>KSR2</i>	rs34965774	12	118,412,373	A	G	0.0581	0.0063	1.5E-21	0.0496	0.0265	1.9E-01
<i>HNF1A</i>	rs1169299	12	121,429,194	C	T	0.0219	0.0050	1.9E-21	0.0656	0.0200	1.1E-04

<i>MPHOSPH9-ZNF664</i>	rs1790116	12	123,618,544	T	G	0.0433	0.0067	2.2E-11	-0.0022	0.0250	9.2E-01
<i>FBRSL1</i>	rs12811407	12	133,069,698	A	G	0.0462	0.0059	2.0E-15	0.0799	0.0223	5.5E-03
<i>SGCG</i>	rs314879	13	23,309,382	C	T	0.0405	0.0062	3.7E-11	0.0101	0.0258	9.7E-01
<i>RNF6</i>	rs34584161	13	26,776,999	A	G	0.0471	0.0055	3.5E-19	0.0386	0.0228	2.1E-03
<i>KL</i>	rs2858980	13	33,554,587	G	A	0.0570	0.0063	6.2E-22	0.0820	0.0262	1.8E-02
<i>DLEU1</i>	rs963740	13	51,096,095	A	T	0.0355	0.0053	3.8E-11	0.0448	0.0220	7.7E-02
<i>OLFM4</i>	rs9568868	13	54,107,583	T	G	0.0467	0.0065	1.5E-12	0.0384	0.0275	2.1E-01
<i>SPRY2</i>	rs1215468	13	80,707,429	A	G	0.0812	0.0055	2.4E-56	0.0402	0.0222	2.7E-01
<i>MIR17HG</i>	rs34165267	13	91,942,919	C	T	0.0495	0.0059	6.7E-21	0.0383	0.0240	3.8E-01
<i>AKAP6</i>	rs12883788	14	33,303,540	T	C	0.0348	0.0051	1.9E-11	0.0116	0.0205	1.4E-01
<i>CLEC14A</i>	rs2183237	14	38,803,756	G	A	0.0401	0.0053	5.0E-15	0.0224	0.0217	3.0E-01
<i>NRXN3</i>	rs8008910	14	79,944,099	A	G	0.0544	0.0069	3.3E-15	-0.0135	0.0258	4.0E-01
<i>MEG3</i>	rs73347525	14	101,255,172	A	G	0.0510	0.0065	1.8E-15	0.0088	0.0262	7.8E-01
<i>MARK3</i>	rs11160699	14	103,252,270	A	G	0.0413	0.0059	5.9E-12	0.0188	0.0260	5.7E-01
<i>RASGRP1</i>	rs12912777	15	38,852,386	T	C	0.0787	0.0099	2.7E-16	0.1142	0.0354	4.9E-03
<i>INFAM2-LTK</i>	rs3743140	15	40,616,742	A	G	0.0489	0.0068	5.0E-16	0.0861	0.0293	4.0E-02
<i>LTK</i>	rs1473781	15	41,818,917	A	G	0.0327	0.0056	2.1E-11	0.0275	0.0214	1.8E-01
<i>ONECUT1-WDR72</i>	rs3825801	15	52,517,714	C	T	0.0454	0.0072	3.8E-11	0.0712	0.0309	1.5E-01
<i>C2CD4A-C2CD4B</i>	rs7163757	15	62,391,608	C	T	0.0571	0.0049	2.4E-37	0.0099	0.0200	7.9E-01
<i>USP3</i>	rs7178762	15	63,871,292	C	T	0.0379	0.0055	9.2E-12	0.0218	0.0209	1.1E-01
<i>MAP2K5</i>	rs4776970	15	68,080,886	A	T	0.0360	0.0053	5.7E-13	0.0486	0.0208	2.0E-03
<i>PTPN9</i>	rs11636031	15	75,815,758	T	C	0.0465	0.0054	4.9E-19	0.0115	0.0228	3.2E-02
<i>HMG20A</i>	rs952472	15	77,776,562	C	A	0.0761	0.0051	4.1E-56	0.0071	0.0211	9.1E-01
<i>AP3S2</i>	rs6496609	15	90,379,632	C	A	0.0636	0.0056	3.2E-34	0.0877	0.0221	8.8E-04
<i>PRC1</i>	rs2890156	15	91,513,157	A	T	0.0690	0.0059	3.8E-34	0.0732	0.0253	1.8E-02
<i>RGMA</i>	rs7167984	15	93,832,067	G	A	0.0440	0.0063	3.4E-13	0.0242	0.0276	3.2E-01
<i>ITFG3</i>	rs6600191	16	295,795	T	C	0.0439	0.0057	2.4E-15	0.0526	0.0260	5.9E-02
<i>CLUAP1</i>	rs12445430	16	3,613,126	T	C	0.0396	0.0058	2.5E-11	0.0295	0.0281	1.3E-01
<i>FAM57B</i>	rs11642430	16	30,045,789	G	C	0.0290	0.0050	6.6E-10	0.0359	0.0201	3.6E-01
<i>FTO</i>	rs55872725	16	53,809,123	T	C	0.1215	0.0055	4.7E-128	0.0554	0.0207	5.5E-02
<i>NFAT5</i>	rs862320	16	69,651,866	C	T	0.0347	0.0055	1.5E-10	0.0194	0.0207	8.5E-02
<i>ZFH3</i>	rs6416749	16	73,100,308	C	T	0.0375	0.0056	1.5E-13	-0.0023	0.0223	5.0E-01
<i>BCAR1</i>	rs72802358	16	75,243,657	G	C	0.0877	0.0090	2.9E-29	0.0825	0.0349	1.7E-01
<i>CMIP</i>	rs2925979	16	81,534,790	T	C	0.0494	0.0054	1.6E-21	0.0282	0.0219	4.5E-01
<i>ZFPM1</i>	rs9937296	16	88,554,480	C	T	0.0424	0.0071	5.3E-10	0.0287	0.0295	3.4E-01

<i>SPG7</i>	rs12920022	16	89,564,055	A	T	0.0420	0.0074	9.9E-10	0.0295	0.0303	2.1E-01
<i>ZZEF1</i>	rs8071043	17	3,988,451	C	T	0.0379	0.0055	4.3E-15	0.0260	0.0217	7.8E-01
<i>SLC16A11-SLC16A13</i>	rs113748381	17	6,953,155	A	G	0.1078	0.0115	2.3E-24	N/A	N/A	N/A
<i>RAI1</i>	rs1108646	17	17,751,478	A	G	0.0394	0.0056	2.8E-13	0.0150	0.0223	7.9E-01
<i>NF1</i>	rs1048317	17	29,704,002	T	C	0.0378	0.005	1.4E-14	0.0178	0.0202	7.5E-01
<i>HNF1B</i>	rs10908278	17	36,099,952	T	A	0.0836	0.0053	7.4E-74	0.0398	0.0221	1.7E-01
<i>MLX</i>	rs684214	17	40,696,915	T	C	0.0397	0.0056	3.0E-13	0.0106	0.0227	7.6E-01
<i>GIP-TTLL6</i>	rs35895680	17	47,060,322	C	A	0.0480	0.0064	2.3E-14	0.0019	0.0231	6.4E-01
<i>ACE</i>	rs57676627	17	62,203,128	T	C	0.0542	0.0087	1.8E-10	0.0556	0.0340	2.9E-01
<i>BPTF</i>	rs9899520	17	65,957,568	A	G	0.0380	0.0056	1.3E-14	0.0034	0.0241	6.0E-01
<i>CYTH1</i>	rs1044486	17	76,792,179	G	A	0.0357	0.0050	3.2E-13	0.0372	0.0199	1.8E-01
<i>LAMA1</i>	rs9948462	18	7,076,836	T	C	0.0371	0.0051	3.9E-15	-0.0110	0.0205	5.6E-01
<i>TCF4</i>	rs72926932	18	53,050,646	C	A	0.0712	0.0116	1.2E-09	0.0688	0.0396	3.9E-01
<i>GRP-MC4R</i>	rs6567160	18	57,829,135	C	T	0.0690	0.0058	1.1E-37	0.0657	0.0233	7.7E-02
<i>BCL2A</i>	rs12454712	18	60,845,884	T	C	0.0461	0.0051	4.1E-20	-0.0215	0.0216	3.1E-02
<i>ZNF236</i>	rs12457906	18	74,555,593	G	A	0.0352	0.0049	6.0E-13	0.0410	0.0205	7.8E-02
<i>UHRF1-PTPRS</i>	rs262549	19	4,951,064	G	C	0.0447	0.0073	2.5E-09	0.0780	0.0272	5.0E-03
<i>MAP2K7</i>	rs2115107	19	7,968,168	A	G	0.0444	0.0051	1.1E-18	0.0550	0.0210	7.3E-02
<i>FARSA</i>	rs3111316	19	13,038,415	A	G	0.0386	0.0053	1.3E-13	0.0126	0.0213	9.0E-01
<i>CILP2-TM6SF2</i>	rs58542926	19	19,379,549	T	C	0.0657	0.0095	1.6E-13	0.0473	0.0376	4.5E-01
<i>ZNF257</i>	rs142395395	19	22,100,706	A	G	0.2070	0.0263	1.2E-15	N/A	N/A	N/A
<i>PEPD</i>	rs10406327	19	33,890,838	C	G	0.0426	0.0049	3.5E-20	0.0365	0.0199	2.7E-01
<i>TOMM40-APOE-GIPR</i>	rs10406431	19	46,157,019	A	G	0.0656	0.0051	8.7E-44	0.0565	0.0212	8.5E-02
<i>ZC3H4</i>	rs3810291	19	47,569,003	A	G	0.0462	0.0054	8.6E-19	0.0276	0.0217	2.3E-01
<i>FOXA2</i>	rs2181063	20	22,427,370	C	G	0.0343	0.0056	5.9E-10	0.0179	0.0241	8.2E-02
<i>RALY</i>	rs4911405	20	32,674,967	T	C	0.0359	0.0057	4.4E-12	0.0362	0.0220	2.4E-03
<i>HNF4A</i>	rs12625671	20	42,994,812	C	T	0.0779	0.0062	9.5E-40	0.0705	0.0278	1.1E-01
<i>EYA2</i>	rs6063046	20	45,596,378	A	G	0.0437	0.0067	1.5E-10	0.0283	0.0237	3.4E-01
<i>CEBPB</i>	rs6091115	20	48,832,020	T	C	0.0473	0.0049	9.3E-23	0.0217	0.0197	5.3E-01
<i>GNAS</i>	rs736266	20	57,387,352	T	A	0.0304	0.0049	6.6E-10	0.0453	0.0200	9.8E-02
<i>MTMR3</i>	rs36575	22	30,205,572	C	T	0.0790	0.0107	1.9E-13	0.1056	0.0404	6.1E-03
<i>YWHAH</i>	rs75307421	22	32,203,334	A	G	0.0960	0.0158	3.1E-11	N/A	N/A	N/A
<i>PNPLA3</i>	rs738408	22	44,324,730	T	C	0.0310	0.0055	5.5E-10	-0.0023	0.0232	6.6E-01
<i>PIM3</i>	rs28691713	22	50,356,302	C	T	0.0484	0.0054	5.9E-22	0.0302	0.0217	6.5E-01

Table S6. Genetic correlation (r_G) from LD-score regression between GDM, T2D and glycaemic traits.

r_G (95% CI) ^a	GDM	T2D	Fasting glucose	Fasting insulin	Fasting proinsulin	2hr glucose (BMI adjusted)	HbA1c	HOMA-B	HOMA-IR
GDM		(0.05, 1.44)	(-0.21, 0.65)	(-0.12, 0.93)	(-0.32, 0.99)	(-0.37, 1.26)	(-0.22, 0.99)	(-0.55, 0.54)	(-0.38, 0.85)
T2D	0.74		(0.47, 0.87)	(0.29, 0.66)	(-0.02, 0.48)	(0.11, 0.59)	(0.41, 0.59)	(-0.19, 0.21)	(0.25, 0.73)
Fasting glucose	0.22	0.67		(0.12, 0.48)	(0.08, 0.64)	(-0.19, 0.35)	(0.21, 0.59)	(-0.67, -0.27)	(0.33, 0.67)
Fasting insulin	0.41	0.48	0.30		(-0.02, 0.52)	(-0.29, 0.29)	(-0.04, 0.38)	(0.95, 1.25)	(1.32, 1.74)
Fasting proinsulin	0.34	0.23	0.36	0.25		(-0.39, 0.37)	(-0.24, 0.36)	(-0.32, 0.30)	(-0.02, 0.54)
2hr glucose (BMI adjusted)	0.44	0.35	0.08	0.00	-0.01		(-0.20, 0.34)	(-0.41, 0.23)	(-0.45, 0.25)
HbA1c	0.39	0.59	0.40	0.17	0.06	0.07		(-0.43, 0.03)	(-0.04, 0.46)
HOMA-B	0.00	0.01	-0.47	1.10	-0.01	-0.09	-0.20		(0.59, 0.83)
HOMA-IR	0.24	0.49	0.50	1.53	0.26	-0.10	0.21	0.71	

CI: Confidence Interval. T2D: type 2 diabetes. HbA1c: glycated haemoglobin. BMI: body mass index. HOMA-B: homeostasis model assessment of β -cell activity; HOMA-IR: homeostasis model assessment of insulin resistance.

^aGenetic correlation obtained from LD-score regression is not bound by -1 to 1 and estimates can therefore be found outside these limits due to high imprecision caused by factors such as low sample size in the GWAS summary statistics used.

Table S7. Impact of lead SNVs at GDM loci on T2D and glycaemic traits.

Locus	Lead SNV	Alleles		GDM ^a		T2D ^b		Fasting glucose ^c		HbA1c ^d	
		Risk	Other	Log-OR (SE)	<i>p</i> -value	Log-OR (SE)	<i>p</i> -value	Beta (SE)	<i>p</i> -value	Beta (SE)	<i>p</i> -value
<i>MTNR1B</i>	rs10830963	G	C	0.3404 (0.0218)	4.3E-54	0.0840 (0.0054)	6.1E-66	0.0772 (0.0019)	1.4E-321	0.0197 (0.0015)	1.5E-36
<i>TCF7L2</i>	rs7903146	T	C	0.1961 (0.0230)	4.0E-16	0.2983 (0.0062)	0	0.0259 (0.0019)	2.0E-35	0.0133 (0.0014)	1.0E-22
<i>CDKAL1</i>	rs9348441	A	T	0.1243 (0.0291)	1.6E-14	0.1541 (0.0053)	6.2E-235	0.0176 (0.0018)	4.4E-20	0.0101 (0.0014)	2.4E-13
<i>CDKN2A-CDKN2B</i>	rs10811662	G	A	0.1329 (0.0255)	4.1E-9	0.1661 (0.0060)	3.5E-166	0.0223 (0.0022)	7.9E-25	0.0127 (0.0017)	3.2E-14
<i>HKDC1</i>	rs9663238	G	A	0.1339 (0.0222)	2.9E-8	0.0139 (0.0054)	8.3E-3	-0.0080 (0.0019)	2.1E-4	0.0037 (0.0014)	1.5E-2

OR: odds-ratio. SE: standard error

^aTrans-ancestry meta-analysis of 5,485 cases and 347,856 controls from the current study.

^bTrans-ancestry meta-analysis of 180,834 cases and 1,159,055 controls from the DIAGRAM Consortium. Mahajan A, Spracklen CN, Zhang W, Ng MC, Petty LE, Kitajima H, et al. Trans-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. medRxiv. 2020

^cEuropean ancestry meta-analysis of 200,622 non-diabetic individuals from the MAGIC Investigators. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet 53: 840–60.

^dEuropean ancestry meta-analysis of 146,806 non-diabetic individuals from the MAGIC Investigators. Chen J, Spracklen CN, Marenne G, Varshney A, Corbin LJ, Luan J, et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet 53: 840–60.

Table S8. Summary statistics from joint fGWAS model of enriched functional and regulatory annotations for GDM association signals from trans-ancestry meta-regression (MR-MEGA).

Annotation^a	Enrichment <i>p</i>-value	Fold-enrichment (95% CI)
Adipose active enhancer 2	0.0019	2.84 (1.55-4.58)
FOXA2 binding site	0.0031	4.63 (1.87-8.89)
Skeletal muscle weak enhancer	0.0098	1.99 (1.19-3.05)
TFAP2A binding site	0.014	4.99 (1.59-10.50)
NFE2 binding site	0.021	10.49 (1.72-30.66)
Protein coding exon	0.032	3.57 (1.13-7.45)
Adipose strong transcription	0.037	1.79 (1.04-2.80)

^aThree categories of functional and regulatory annotations were considered: (i) genic regions; (ii) chromatin immuno-precipitation sequence (ChIP-seq) binding sites for 165 transcription factors; and (iii) 13 unique and recurrent chromatin states in four diabetes-relevant tissues (pancreatic islets, liver, adipose, and skeletal muscle). Details are provided in the **Supplementary Materials and Methods**.

Table S9. Genome-wide significant associations ($p < 5 \times 10^{-8}$) of 99% credible set variants at the *HKDC1* locus with other traits.

SNV	Chr	Position (bp, b37)	Alleles		Trait	beta	p-value	Sample size	Data source
			GDM risk	other					
rs10998647	10	70,977,308	G	T	Lymphocyte count	-0.024	1.1×10^{-9}	173,480	PMID: 27863252
rs10998648	10	70,977,395	C	A	Comparative height size at age 10	0.011	3.4×10^{-9}	332,021	UK Biobank
rs10823318	10	70,979,924	T	A	Birth weight	0.030	2.9×10^{-18}	193,063	UK Biobank
					Comparative body size at age 10	0.010	2.8×10^{-8}	331,693	UK Biobank
rs4746822	10	70,982,941	T	C	2-hour plasma glucose in pregnancy	0.280	1.0×10^{-22}	N/A	PMID: 23903356
rs35199395	10	70,983,936	C	G	Birth weight of first child	0.029	3.9×10^{-9}	145,558	UK Biobank

Table S10. 99% credible set variants at the *HKDC1* locus that are lead *cis*-eQTL variants in samples from the Genotype Tissue Expression (GTEx) Project.

Gene	Tissue	Lead eQTL variant	Chr	Position (bp, b37)	Alleles		Association with gene expression	
					GDM risk	Other	Beta	p-value
<i>HKDC1</i>	Adipose (subcutaneous)	rs4746822	10	70,982,941	T	C	-0.28	1.3x10 ⁻⁸
	Adipose (visceral)	rs9663238	10	70,983,629	G	A	-0.32	1.9x10 ⁻⁸
	Breast (mammary)	rs5030937	10	70,975,897	T	C	-0.41	8.6x10 ⁻¹⁰
	Esophagus mucosa	rs10762264	10	70,976,833	A	G	-0.30	1.2x10 ⁻⁹
	Whole blood	rs4746822	10	70,982,941	T	C	-0.42	5.9x10 ⁻²⁶
<i>SUPV3L1</i>	Lung	rs5030937	10	70,975,897	T	C	-0.18	1.9x10 ⁻⁹
	Whole blood	rs5030937	10	70,975,897	T	C	-0.21	1.1x10 ⁻²²

Table S11. Effect estimates of metabolic traits on GDM from MR analyses.

Metabolic trait	Category	Subcategory	MR method	SNVs	Beta	SE	p-value	q-value	Sample size	Sex	PMID
Body mass index	Risk factor	Anthropometric	RE IVW	36	0.688	0.112	4.8x10 ⁻⁷	6.8x10 ⁻⁵	171,977	Women	25673413
Triglycerides	Metabolites	NA	FE IVW	175	0.190	0.065	0.0035	0.25	NA	Both	NA
X-14626	Metabolites	Unknown metabolite	RE IVW	2	-1.416	0.010	0.0043	0.25	6,904	Both	24816252
Obesity class 1	Risk factor	Anthropometric	Weighted median	17	0.231	0.084	0.0059	0.25	98,697	Both	23563607
Alanine	Metabolites	Amino acid	Weighted median	6	-0.492	0.182	0.0070	0.25	24,796	Both	27005778
X-13215	Metabolites	Unknown metabolite	RE IVW	2	0.660	0.009	0.0090	0.25	6,305	Both	24816252
X-13429	Metabolites	Unknown metabolite	RE IVW	3	-0.507	0.049	0.0093	0.25	6,344	Both	24816252
Uridine	Metabolites	Nucleotide	RE IVW	3	2.706	0.263	0.0093	0.25	7,800	Both	24816252
Childhood obesity	Risk factor	Anthropometric	RE IVW	5	0.264	0.057	0.0095	0.25	13,848	Both	22484627
Waist-to-hip ratio	Risk factor	Anthropometric	RE IVW	21	0.533	0.187	0.0098	0.25	118,003	Women	25673412
N2,N2-dimethylguanosine	Metabolites	Nucleotide	RE IVW	2	1.443	0.027	0.012	0.27	5,228	Both	24816252
X-12456	Metabolites	Unknown metabolite	RE IVW	2	-0.676	0.013	0.012	0.27	4,774	Both	24816252
Overweight	Risk factor	Anthropometric	Penalised median	14	0.296	0.122	0.015	0.31	158,855	Both	23563607
Extreme body mass index	Risk factor	Anthropometric	Penalised median	7	0.131	0.057	0.021	0.39	16,068	Both	23563607
Hip circumference	Risk factor	Anthropometric	Simple median	17	0.585	0.259	0.024	0.40	127,997	Women	25673412
Waist circumference	Risk factor	Anthropometric	Simple median	17	0.585	0.259	0.024	0.40	127,997	Women	25673412
Triglycerides in large VLDL	Metabolites	Lipid	Simple median	8	-0.305	0.143	0.033	0.52	21,239	Both	27005778
Triglycerides in very large VLDL	Metabolites	Lipid	Simple median	7	-0.353	0.170	0.038	0.57	21,548	Both	27005778
Tetradecanedioate	Metabolites	Lipid	RE IVW	3	-0.773	0.173	0.047	0.66	6,046	Both	24816252
Gamma glutamyltransferase	Metabolites	NA	Simple mean	221	0.154	0.079	0.052	0.66	NA	Both	NA
X-12798	Metabolites	Unknown metabolite	RE IVW	3	-0.217	0.052	0.054	0.66	7,552	Both	24816252
Hexadecanedioate	Metabolites	Lipid	RE IVW	3	-0.919	0.227	0.056	0.66	6,887	Both	24816252
X-12510--2-aminooctanoic acid	Metabolites	Amino acid	RE IVW	3	0.108	0.027	0.056	0.66	7,566	Both	24816252
Total lipids in large VLDL	Metabolites	Lipid	Simple median	9	-0.279	0.149	0.061	0.67	18,960	Both	27005778
Hexanoylcarnitine	Metabolites	Lipid	RE IVW	4	0.397	0.139	0.064	0.67	7,786	Both	24816252
X-11491	Metabolites	Unknown metabolite	RE IVW	3	-0.698	0.191	0.067	0.67	6,584	Both	24816252
Indoleacetate	Metabolites	Amino acid	RE IVW	2	1.178	0.128	0.069	0.67	7,618	Both	24816252
Obesity class 2	Risk factor	Anthropometric	Simple median	11	0.125	0.070	0.073	0.67	72,546	Both	23563607
X-10510	Metabolites	Unknown metabolite	RE IVW	3	-1.075	0.308	0.073	0.67	7,792	Both	24816252
Calcium	Metabolites	NA	Weighted mode	137	3.529	1.956	0.073	0.67	NA	Both	NA
X-11538	Metabolites	Unknown metabolite	RE IVW	3	-0.689	0.203	0.077	0.68	7,804	Both	24816252
Sphingomyelins	Metabolites	Lipid	Penalised median	6	-0.232	0.134	0.085	0.73	13,476	Both	27005778
X-08402	Metabolites	Unknown metabolite	RE IVW	2	-0.601	0.089	0.094	0.77	7,726	Both	24816252
X-12728	Metabolites	Unknown metabolite	RE IVW	5	-0.033	0.015	0.10	0.77	537	Both	24816252
Dehydroisoandrosterone sulfate (DHEA-S)	Metabolites	Lipid	RE IVW	2	-0.341	0.056	0.10	0.77	7,793	Both	24816252
Concentration of chylomicrons and largest VLDL particles	Metabolites	Lipid	RE IVW	5	-0.198	0.096	0.11	0.77	18,960	Both	27005778
1-linoleoylglycerophosphoethanolamine*	Metabolites	Lipid	RE IVW	2	-1.606	0.283	0.11	0.77	7,817	Both	24816252
Free cholesterol to esterified cholesterol ratio	Metabolites	Lipid	Simple mode	10	-0.196	0.111	0.11	0.77	13,497	Both	27005778
Serine	Metabolites	Amino acid	RE IVW	2	0.792	0.141	0.11	0.77	7,796	Both	24816252
Obesity class 3	Risk factor	Anthropometric	RE IVW	2	0.163	0.030	0.12	0.77	50,364	Both	23563607

Omega-6 fatty acids	Metabolites	Fatty acid	Penalised median	8	-0.162	0.104	0.12	0.77	13,506	Both	27005778
X-12092	Metabolites	Unknown metabolite	RE IVW	5	0.195	0.100	0.12	0.77	7,500	Both	24816252
X-12188	Metabolites	Unknown metabolite	RE IVW	2	0.159	0.032	0.13	0.77	832	Both	24816252
Valine	Metabolites	Amino acid	RE IVW	5	0.277	0.147	0.13	0.77	24,900	Both	27005778
X-12063	Metabolites	Unknown metabolite	Simple median	6	-0.347	0.233	0.14	0.77	7,197	Both	24816252
Laurate (12:0)	Metabolites	Fatty acid	RE IVW	2	2.525	0.557	0.14	0.77	7,793	Both	24816252
Succinylcarnitine	Metabolites	Energy	Simple mode	7	-1.563	0.919	0.14	0.77	6,948	Both	24816252
Phospholipids in very large VLDL	Metabolites	Lipid	Simple median	8	-0.210	0.142	0.14	0.77	21,237	Both	27005778
Total cholesterol in large VLDL	Metabolites	Lipid	Simple median	7	-0.255	0.174	0.14	0.77	21,235	Both	27005778
X-11905	Metabolites	Unknown metabolite	RE IVW	2	-0.726	0.167	0.14	0.77	4,761	Both	24816252
Cholesterol	Metabolites	Lipid	RE IVW	2	-2.873	0.665	0.14	0.77	7,813	Both	24816252
ADSGEGDFXAEGGGVR*	Metabolites	Peptide	RE IVW	2	-0.399	0.092	0.15	0.77	5,588	Both	24816252
Acetylphosphate	Metabolites	Energy	RE IVW	2	-1.665	0.396	0.15	0.77	7,789	Both	24816252
Palmitoyl sphingomyelin	Metabolites	Lipid	RE IVW	2	-3.063	0.733	0.15	0.77	7,814	Both	24816252
Albumin	Metabolites	Protein	RE IVW	2	-0.248	0.062	0.16	0.77	18,960	Both	27005778
Octadecanedioate	Metabolites	Lipid	RE IVW	2	-1.357	0.340	0.16	0.77	7,300	Both	24816252
5alpha-androstan-3beta,17beta-diol disulfate	Metabolites	Lipid	RE IVW	3	-0.366	0.168	0.16	0.77	7,345	Both	24816252
Apolipoprotein B	Metabolites	NA	RE Egger	114	-0.811	0.577	0.16	0.77	NA	Both	NA
X-18601	Metabolites	Unknown metabolite	RE IVW	3	-1.035	0.478	0.16	0.77	7,663	Both	24816252
X-14304--leucylalanine	Metabolites	Peptide	RE IVW	2	1.188	0.319	0.17	0.78	2,434	Both	24816252
Free cholesterol in large VLDL	Metabolites	Lipid	Simple mean	9	-0.187	0.126	0.18	0.78	21,238	Both	27005778
Direct bilirubin	Metabolites	NA	Simple median	53	-0.313	0.235	0.18	0.78	NA	Both	NA
Alanine aminotransferase	Metabolites	NA	FE IVW	73	0.010	0.008	0.18	0.78	NA	Both	NA
Total fatty acids	Metabolites	Fatty acid	RE Egger	10	-0.758	0.523	0.19	0.78	13,505	Both	27005778
X-14189--leucylalanine	Metabolites	Peptide	RE IVW	2	1.041	0.315	0.19	0.78	2,745	Both	24816252
Average number of methylene groups in a fatty acid chain	Metabolites	Fatty acid	RE IVW	3	-0.280	0.142	0.19	0.78	19,021	Both	27005778
Triglycerides in chylomicrons and largest VLDL particles	Metabolites	Lipid	Simple median	8	-0.190	0.144	0.19	0.78	21,540	Both	27005778
Omega-7, omega-9 and saturated fatty acids	Metabolites	Fatty acid	RE IVW	5	-0.133	0.087	0.20	0.81	13,506	Both	27005778
Mono-unsaturated fatty acids	Metabolites	Fatty acid	RE IVW	5	-0.307	0.202	0.20	0.81	13,535	Both	27005778
Lipoprotein A	Metabolites	NA	RE IVW	4	0.003	0.002	0.21	0.81	NA	Both	NA
X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide	Metabolites	Amino acid	RE IVW	4	-0.583	0.367	0.21	0.81	7,812	Both	24816252
Tryptophan	Metabolites	Amino acid	Simple median	17	2.003	1.608	0.21	0.81	7,804	Both	24816252
X-11529	Metabolites	Unknown metabolite	RE IVW	2	-0.207	0.072	0.21	0.81	6,664	Both	24816252
Total lipids in medium VLDL	Metabolites	Lipid	Simple median	6	-0.176	0.142	0.22	0.81	19,273	Both	27005778
Ratio of bisallylic groups to double bonds	Metabolites	Metabolites ratio	RE IVW	4	0.166	0.107	0.22	0.81	13,524	Both	27005778
X-11593--O-methylascorbate*	Metabolites	Cofactors and vitamins	Simple mean	6	-0.518	0.371	0.22	0.81	7,788	Both	24816252
Triglycerides in medium VLDL	Metabolites	Lipid	Simple median	9	-0.160	0.133	0.23	0.81	21,241	Both	27005778
X-11327	Metabolites	Unknown metabolite	RE IVW	2	-2.262	0.854	0.23	0.81	7,671	Both	24816252
Ratio of bisallylic groups to total fatty acids	Metabolites	Fatty acid	RE IVW	4	0.243	0.163	0.23	0.81	13,171	Both	27005778
Hydroxyisovaleroyl carnitine	Metabolites	Amino acid	RE IVW	2	0.954	0.372	0.24	0.81	5,588	Both	24816252
Average number of double bonds in a fatty acid chain	Metabolites	Fatty acid	RE IVW	5	0.185	0.133	0.24	0.81	15,728	Both	27005778
Mean diameter for LDL particles	Metabolites	Lipid	RE IVW	3	0.118	0.070	0.24	0.81	19,273	Both	27005778
Transferrin	Risk factor	Metal	Simple mode	7	0.121	0.093	0.24	0.81	23,986	Both	25352340

X-11793--oxidized bilirubin*	Metabolites	Cofactors and vitamins	RE IVW	2	0.288	0.118	0.25	0.81	7,611	Both	24816252
Citrulline	Metabolites	Amino acid	RE IVW	4	-1.799	1.258	0.25	0.81	7,773	Both	24816252
X-02269	Metabolites	Unknown metabolite	RE IVW	3	0.668	0.419	0.25	0.81	7,701	Both	24816252
4-androsten-3beta,17beta-diol disulfate 1*	Metabolites	Lipid	RE IVW	2	-0.124	0.052	0.25	0.81	7,804	Both	24816252
Other polyunsaturated fatty acids than 18:2	Metabolites	Fatty acid	Weighted mode	8	-0.192	0.156	0.26	0.81	13,549	Both	27005778
Phospholipids in IDL	Metabolites	Lipid	RE IVW	17	-0.061	0.052	0.26	0.81	21,559	Both	27005778
Body fat	Risk factor	Anthropometric	Simple mean	10	0.416	0.347	0.26	0.81	100,716	Both	26833246
Average number of methylene groups per double bond	Metabolites	Metabolites ratio	RE IVW	5	-0.161	0.123	0.26	0.81	13,532	Both	27005778
Glutaroyl carnitine	Metabolites	Amino acid	Simple median	7	-0.571	0.522	0.27	0.83	7,701	Both	24816252
N-acetylglycine	Metabolites	Amino acid	RE IVW	2	0.142	0.066	0.28	0.83	7,135	Both	24816252
1-eicosatrienoylglycerophosphocholine*	Metabolites	Lipid	RE IVW	2	-0.741	0.346	0.28	0.83	7,809	Both	24816252
Gamma-glutamyltyrosine	Metabolites	Peptide	RE IVW	5	-1.646	1.323	0.28	0.83	7,468	Both	24816252
Cis-4-decenoyl carnitine	Metabolites	Lipid	RE IVW	2	0.500	0.241	0.29	0.84	7,660	Both	24816252
Creatinine	Metabolites	Amino acid	Weighted mode	6	-0.313	0.267	0.29	0.85	24,810	Both	27005778
1,5-anhydroglucitol (1,5-AG)	Metabolites	Carbohydrate	RE IVW	3	-0.850	0.613	0.30	0.85	7,746	Both	24816252
18:2, linoleic acid (LA)	Metabolites	Fatty acid	Simple mode	10	-0.171	0.156	0.30	0.85	13,527	Both	27005778
Triglycerides in small VLDL	Metabolites	Lipid	Simple median	10	-0.132	0.129	0.31	0.86	21,558	Both	27005778
X-11423--O-sulfo-L-tyrosine	Metabolites	Amino acid	RE IVW	2	0.959	0.520	0.32	0.87	7,765	Both	24816252
Aspartate aminotransferase	Metabolites	NA	Simple mode	164	0.314	0.313	0.32	0.87	NA	Both	NA
Immunoglobulin G index levels	Risk factor	Immune system	RE IVW	2	0.023	0.013	0.32	0.87	938	Both	25616667
Triglycerides in very small VLDL	Metabolites	Lipid	Simple median	14	-0.096	0.098	0.32	0.87	19,273	Both	27005778
Heptanoate (7:0)	Metabolites	Fatty acid	RE IVW	2	0.699	0.397	0.33	0.88	7,802	Both	24816252
Total lipids in small LDL	Metabolites	Lipid	Simple median	12	-0.086	0.090	0.34	0.88	19,273	Both	27005778
Free cholesterol in IDL	Metabolites	Lipid	RE IVW	16	-0.061	0.062	0.34	0.88	21,559	Both	27005778
X-11469	Metabolites	Unknown metabolite	RE IVW	3	0.593	0.483	0.34	0.88	7,779	Both	24816252
Total cholesterol in very large HDL	Metabolites	Lipid	Simple median	8	0.108	0.114	0.35	0.88	21,540	Both	27005778
Birth weight	Risk factor	Anthropometric	Simple mode	37	-0.342	0.360	0.35	0.88	143,677	Both	27680694
Zinc	Risk factor	Metal	RE IVW	2	-0.146	0.089	0.35	0.88	2,603	Both	23720494
Isobutyrylcarnitine	Metabolites	Amino acid	RE IVW	3	-0.369	0.306	0.35	0.88	7,812	Both	24816252
Serum total cholesterol	Metabolites	Lipid	RE IVW	18	-0.091	0.098	0.37	0.89	21,491	Both	27005778
Asparagine	Metabolites	Amino acid	RE IVW	2	0.161	0.105	0.37	0.89	7,761	Both	24816252
Cholesterol esters in very large HDL	Metabolites	Lipid	Weighted median	7	0.098	0.110	0.37	0.89	19,273	Both	27005778
X-11445--5-alpha-pregnan-3beta,20alpha-disulfate	Metabolites	Lipid	RE IVW	3	-0.422	0.374	0.38	0.89	2,570	Both	24816252
Concentration of large VLDL particles	Metabolites	Lipid	Simple mean	8	-0.145	0.157	0.39	0.89	18,960	Both	27005778
X-12556	Metabolites	Unknown metabolite	RE IVW	2	0.586	0.408	0.39	0.89	7,483	Both	24816252
X-12644	Metabolites	Unknown metabolite	RE IVW	3	-1.390	1.303	0.40	0.89	7,795	Both	24816252
X-12100--hydroxytryptophan*	Metabolites	Amino acid	RE IVW	2	0.336	0.243	0.40	0.89	7,499	Both	24816252
ADpSGEGDFXAEGGGVR*	Metabolites	Peptide	RE IVW	2	-0.234	0.169	0.40	0.89	3,939	Both	24816252
X-13435	Metabolites	Unknown metabolite	RE IVW	2	-0.793	0.576	0.40	0.89	6,970	Both	24816252
Free cholesterol in medium VLDL	Metabolites	Lipid	Simple median	7	-0.128	0.153	0.40	0.89	21,240	Both	27005778
Triglycerides in IDL	Metabolites	Lipid	Simple mean	16	0.054	0.064	0.41	0.89	19,273	Both	27005778
Pyroglutamine*	Metabolites	Amino acid	RE IVW	4	-0.278	0.292	0.41	0.89	7,800	Both	24816252
X-03094	Metabolites	Unknown metabolite	RE IVW	5	-1.270	1.399	0.42	0.89	7,804	Both	24816252

Gamma-glutamylglutamine	Metabolites	Peptide	RE IVW	3	2.340	2.342	0.42	0.89	7,662	Both	24816252
Concentration of small VLDL particles	Metabolites	Lipid	RE IVW	13	-0.072	0.088	0.43	0.89	19,273	Both	27005778
X-11261	Metabolites	Unknown metabolite	RE IVW	2	-0.486	0.392	0.43	0.89	7,771	Both	24816252
X-12696	Metabolites	Unknown metabolite	RE IVW	2	-0.886	0.730	0.44	0.89	7,409	Both	24816252
4-androsten-3beta,17beta-diol disulfate 2*	Metabolites	Lipid	RE IVW	2	-0.670	0.556	0.44	0.89	7,776	Both	24816252
1-arachidonoylglycerophosphoethanolamine*	Metabolites	Lipid	RE IVW	3	1.179	1.242	0.44	0.89	7,798	Both	24816252
Phospholipids in large HDL	Metabolites	Lipid	Simple median	9	0.080	0.105	0.45	0.89	19,273	Both	27005778
Octanoylcarnitine	Metabolites	Lipid	RE IVW	3	0.342	0.365	0.45	0.89	7,790	Both	24816252
Total lipids in large HDL	Metabolites	Lipid	Simple median	9	0.077	0.103	0.45	0.89	19,273	Both	27005778
X-11440	Metabolites	Unknown metabolite	RE IVW	3	-0.112	0.123	0.46	0.89	7,686	Both	24816252
Serum total triglycerides	Metabolites	Lipid	Simple mode	8	-0.155	0.198	0.46	0.89	21,545	Both	27005778
Lactate	Metabolites	Carbohydrate	RE IVW	2	-0.950	0.843	0.46	0.89	24,871	Both	27005778
Acetylcarnitine	Metabolites	Lipid	RE IVW	2	0.299	0.265	0.46	0.89	7,805	Both	24816252
X-08988	Metabolites	Unknown metabolite	RE IVW	2	0.665	0.590	0.46	0.89	7,776	Both	24816252
Concentration of large HDL particles	Metabolites	Lipid	Simple median	9	0.076	0.104	0.47	0.89	19,273	Both	27005778
Mean diameter for HDL particles	Metabolites	Lipid	Simple median	11	0.064	0.090	0.47	0.89	19,273	Both	27005778
Histidine	Metabolites	Amino acid	RE IVW	5	-0.129	0.165	0.48	0.89	19,244	Both	27005778
Phospholipids in medium VLDL	Metabolites	Lipid	Simple median	9	-0.106	0.150	0.48	0.89	21,240	Both	27005778
HDL cholesterol	Metabolites	NA	FE Egger	171	-0.216	0.310	0.49	0.89	NA	Both	NA
Decanoylcarnitine	Metabolites	Lipid	RE IVW	3	0.359	0.424	0.49	0.89	7,766	Both	24816252
X-12093	Metabolites	Unknown metabolite	RE IVW	2	0.204	0.201	0.50	0.89	2,854	Both	24816252
Caprylate (8:0)	Metabolites	Fatty acid	RE IVW	2	-3.331	3.300	0.50	0.89	7,802	Both	24816252
Leptin	Risk factor	Hormone	Wald ratio	1	0.636	0.636	0.50	0.89	32,161	Both	26833098
X-11334	Metabolites	Unknown metabolite	Wald ratio	1	1.407	1.407	0.50	0.89	5,462	Both	24816252
X-09789	Metabolites	Unknown metabolite	Wald ratio	1	0.808	0.808	0.50	0.89	7,805	Both	24816252
X-11444	Metabolites	Unknown metabolite	Wald ratio	1	0.253	0.253	0.50	0.89	7,758	Both	24816252
1-arachidonoylglycerophosphocholine*	Metabolites	Lipid	Wald ratio	1	1.370	1.370	0.50	0.89	7,507	Both	24816252
Epiandrosterone sulfate	Metabolites	Lipid	Wald ratio	1	-0.199	-0.199	0.50	0.89	7,769	Both	24816252
X-13859	Metabolites	Unknown metabolite	Wald ratio	1	3.673	3.673	0.50	0.89	7,002	Both	24816252
Glucose	Metabolites	Carbohydrate	Wald ratio	1	0.650	0.650	0.50	0.89	24,679	Both	27005778
Isoleucine	Metabolites	Amino acid	Wald ratio	1	-1.166	-1.166	0.50	0.89	24,776	Both	27005778
Leucine	Metabolites	Amino acid	Wald ratio	1	-0.556	-0.556	0.50	0.89	24,728	Both	27005778
Total bilirubin	Metabolites	NA	Simple median	57	-0.031	0.046	0.51	0.89	NA	Both	NA
Glutamine	Metabolites	Amino acid	RE IVW	5	0.168	0.230	0.51	0.89	24,462	Both	27005778
10-undecenoate (11:1n1)	Metabolites	Fatty acid	RE IVW	2	0.846	0.877	0.51	0.89	7,806	Both	24816252
Erythronate*	Metabolites	Carbohydrate	RE IVW	3	0.665	0.858	0.52	0.89	7,752	Both	24816252
Phospholipids in chylomicrons and largest VLDL particles	Metabolites	Lipid	Simple mode	6	-0.149	0.217	0.52	0.89	21,542	Both	27005778
Proline	Metabolites	Amino acid	RE IVW	3	-0.201	0.262	0.52	0.89	7,816	Both	24816252
Height	Risk factor	Anthropometric	RE IVW	52	-0.063	0.101	0.54	0.89	73,137	Women	23754948
X-12855	Metabolites	Unknown metabolite	RE IVW	2	-0.387	0.434	0.54	0.89	5,120	Both	24816252
X-11204	Metabolites	Unknown metabolite	RE IVW	2	1.569	1.761	0.54	0.89	7,799	Both	24816252
4-methyl-2-oxopentanoate	Metabolites	Amino acid	RE IVW	2	2.059	2.313	0.54	0.89	7,776	Both	24816252
Gamma-glutamylphenylalanine	Metabolites	Peptide	RE IVW	2	1.919	2.157	0.54	0.89	7,753	Both	24816252

22:6, docosahexaenoic acid	Metabolites	Fatty acid	RE IVW	5	0.133	0.199	0.54	0.89	13,499	Both	27005778
Isovalerylcarnitine	Metabolites	Amino acid	RE IVW	3	0.302	0.416	0.54	0.89	7,789	Both	24816252
X-13431--nonanoylcarnitine*	Metabolites	Lipid	RE IVW	2	0.080	0.092	0.54	0.89	6,591	Both	24816252
Concentration of small LDL particles	Metabolites	Lipid	Simple median	9	-0.055	0.091	0.55	0.89	19,273	Both	27005778
N-acetylmethionine	Metabolites	Amino acid	RE IVW	2	0.238	0.277	0.55	0.89	7,574	Both	24816252
Betaine	Metabolites	Amino acid	RE IVW	3	-0.282	0.397	0.55	0.89	7,806	Both	24816252
X-11315	Metabolites	Unknown metabolite	RE IVW	3	0.360	0.525	0.56	0.90	7,785	Both	24816252
Total cholesterol in HDL	Metabolites	Lipid	Simple median	11	0.079	0.137	0.57	0.90	21,555	Both	27005778
Acetoacetate	Metabolites	Keto acid	RE IVW	2	0.407	0.522	0.58	0.91	19,262	Both	27005778
Free cholesterol in large HDL	Metabolites	Lipid	RE IVW	13	0.055	0.098	0.59	0.92	21,559	Both	27005778
Phospholipids in very large HDL	Metabolites	Lipid	RE IVW	15	0.041	0.075	0.59	0.92	19,273	Both	27005778
Vitamin D	Metabolites	NA	Simple mean	50	-0.063	0.119	0.60	0.92	NA	Both	NA
Phospholipids in medium HDL	Metabolites	Lipid	RE IVW	5	0.073	0.129	0.60	0.92	21,558	Both	27005778
Total lipids in LDL	Metabolites	Lipid	Penalised median	16	-0.022	0.041	0.60	0.92	19,273	Both	27005778
Dihomo-linolenate (20:3n3 or n6)	Metabolites	Fatty acid	RE IVW	2	-0.617	0.855	0.60	0.92	7,805	Both	24816252
Levulinate (4-oxovalerate)	Metabolites	Amino acid	RE IVW	2	-0.486	0.679	0.60	0.92	6,982	Both	24816252
Glycoprotein acetyls	Metabolites	Protein	RE IVW	5	-0.151	0.272	0.61	0.92	19,270	Both	27005778
Concentration of medium HDL particles	Metabolites	Lipid	RE IVW	4	0.099	0.176	0.61	0.92	19,273	Both	27005778
Total lipids in small VLDL	Metabolites	Lipid	Simple median	9	-0.048	0.097	0.62	0.93	19,273	Both	27005778
Total lipids in very large HDL	Metabolites	Lipid	Weighted median	13	-0.038	0.078	0.62	0.93	19,273	Both	27005778
Birth length	Risk factor	Anthropometric	RE IVW	2	0.096	0.145	0.63	0.93	28,459	Both	25281659
Total lipids in small HDL	Metabolites	Lipid	RE IVW	6	-0.105	0.205	0.63	0.93	19,273	Both	27005778
Total protein	Metabolites	NA	Simple mode	162	-0.175	0.368	0.63	0.93	NA	Both	NA
4-acetamidobutanoate	Metabolites	Amino acid	RE IVW	2	0.586	0.925	0.64	0.93	6,930	Both	24816252
Total lipids in medium HDL	Metabolites	Lipid	RE IVW	4	0.085	0.168	0.65	0.94	19,273	Both	27005778
X-11792	Metabolites	Unknown metabolite	RE IVW	3	-0.063	0.121	0.65	0.94	2,442	Both	24816252
Tyrosine	Metabolites	Amino acid	RE IVW	3	-0.064	0.123	0.66	0.94	24,925	Both	27005778
Phospholipids in large VLDL	Metabolites	Lipid	Penalised median	6	-0.058	0.134	0.66	0.94	21,239	Both	27005778
Free cholesterol	Metabolites	Lipid	Penalised median	10	-0.018	0.042	0.67	0.94	13,497	Both	27005778
Total lipids in very small VLDL	Metabolites	Lipid	RE IVW	16	0.016	0.037	0.67	0.94	19,273	Both	27005778
Phenylalanine	Metabolites	Amino acid	RE IVW	3	-0.061	0.128	0.68	0.94	22,663	Both	27005778
IGF-1	Metabolites	NA	Weighted mode	236	-0.064	0.156	0.68	0.94	NA	Both	NA
Kynurenine	Metabolites	Amino acid	RE IVW	3	-0.531	1.127	0.68	0.94	7,816	Both	24816252
Extreme height	Risk factor	Anthropometric	Simple median	41	-0.012	0.031	0.69	0.94	16,196	Both	23563607
Free cholesterol in small VLDL	Metabolites	Lipid	Simple median	10	-0.036	0.092	0.69	0.94	21,559	Both	27005778
Concentration of small HDL particles	Metabolites	Lipid	RE IVW	4	-0.118	0.274	0.70	0.94	19,273	Both	27005778
Concentration of very large HDL particles	Metabolites	Lipid	Simple median	8	0.038	0.098	0.70	0.94	19,273	Both	27005778
Total phosphoglycerides	Metabolites	Lipid	RE IVW	7	-0.070	0.172	0.70	0.94	13,519	Both	27005778
Stearate (18:0)	Metabolites	Fatty acid	RE IVW	2	1.431	2.833	0.70	0.94	7,803	Both	24816252
Alkaline phosphatase	Metabolites	NA	Weighted mode	168	0.002	0.004	0.70	0.94	NA	Both	NA
Alpha-hydroxyisovalerate	Metabolites	Amino acid	RE IVW	3	0.418	0.965	0.71	0.94	7,668	Both	24816252
Cystatin C	Metabolites	NA	Simple mode	226	-0.128	0.349	0.72	0.94	NA	Both	NA
SHBG	Metabolites	NA	Penalised mode	139	0.002	0.007	0.72	0.94	NA	Both	NA

Bradykinin, des-arg(9)	Metabolites	Peptide	RE IVW	3	-0.039	0.094	0.72	0.94	4,570	Both	24816252
Total cholesterol in IDL	Metabolites	Lipid	Simple median	17	-0.028	0.077	0.72	0.94	19,273	Both	27005778
1-arachidonoylglycerophosphoinositol*	Metabolites	Lipid	RE IVW	4	-0.509	1.313	0.72	0.94	7,797	Both	24816252
HWESASXX*	Metabolites	Peptide	RE IVW	2	-0.310	0.683	0.73	0.94	7,700	Both	24816252
Total cholesterol in medium VLDL	Metabolites	Lipid	Simple median	9	-0.042	0.122	0.73	0.94	21,551	Both	27005778
Phospholipids in very small VLDL	Metabolites	Lipid	RE IVW	16	-0.017	0.053	0.75	0.94	19,273	Both	27005778
Cholesterol esters in medium VLDL	Metabolites	Lipid	Penalised median	10	-0.032	0.100	0.75	0.94	19,273	Both	27005778
Testosterone	Metabolites	NA	Simple mode	62	-0.223	0.706	0.75	0.94	NA	Both	NA
Myo-inositol	Metabolites	Lipid	RE IVW	2	-0.931	2.352	0.76	0.94	7,803	Both	24816252
Citrate	Metabolites	Energy	RE IVW	5	0.038	0.116	0.76	0.94	24,770	Both	27005778
Total cholesterol in small LDL	Metabolites	Lipid	Penalised median	12	-0.014	0.045	0.76	0.94	21,556	Both	27005778
1-palmitoylglycerophosphoethanolamine	Metabolites	Lipid	RE IVW	2	-0.317	0.816	0.76	0.94	7,763	Both	24816252
X-12844	Metabolites	Unknown metabolite	RE IVW	3	0.058	0.169	0.76	0.94	7,768	Both	24816252
Phospholipids in small VLDL	Metabolites	Lipid	Penalised median	10	-0.030	0.099	0.76	0.94	21,551	Both	27005778
Phospholipids in medium LDL	Metabolites	Lipid	Simple median	13	-0.027	0.090	0.77	0.94	21,558	Both	27005778
Free cholesterol in large LDL	Metabolites	Lipid	Simple median	15	-0.025	0.084	0.77	0.94	21,555	Both	27005778
Total cholesterol in LDL	Metabolites	Lipid	Simple median	17	-0.025	0.083	0.77	0.94	21,559	Both	27005778
Apolipoprotein A	Metabolites	NA	Simple mode	160	0.294	0.989	0.77	0.94	NA	Both	NA
Apolipoprotein B	Metabolites	Protein	Simple mode	13	-0.030	0.106	0.78	0.95	20,690	Both	27005778
Cholesterol esters in large VLDL	Metabolites	Lipid	Simple median	19	0.023	0.083	0.78	0.95	19,273	Both	27005778
Androsterone sulfate	Metabolites	Lipid	RE IVW	3	-0.055	0.189	0.80	0.96	7,785	Both	24816252
Concentration of very small VLDL particles	Metabolites	Lipid	RE IVW	16	-0.018	0.069	0.80	0.96	19,273	Both	27005778
Propionylcarnitine	Metabolites	Lipid	RE IVW	4	-0.198	0.725	0.80	0.96	7,813	Both	24816252
Triglycerides in small HDL	Metabolites	Lipid	Weighted median	8	0.027	0.109	0.80	0.96	21,558	Both	27005778
X-12524	Metabolites	Unknown metabolite	RE IVW	2	0.276	0.875	0.81	0.96	7,809	Both	24816252
LDL direct	Metabolites	NA	Simple mode	105	0.078	0.337	0.82	0.96	NA	Both	NA
3-dehydrocarnitine*	Metabolites	Lipid	RE IVW	2	-0.266	0.918	0.82	0.96	7,809	Both	24816252
Extreme waist-to-hip ratio	Risk factor	Anthropometric	RE IVW	2	0.018	0.063	0.82	0.96	10,255	Both	23563607
Weight	Risk factor	Anthropometric	Simple median	10	0.055	0.246	0.82	0.96	73,137	Women	23754948
X-13496	Metabolites	Unknown metabolite	RE IVW	2	0.904	3.272	0.83	0.96	7,656	Both	24816252
Triglycerides in very large HDL	Metabolites	Lipid	FE IVW	12	0.007	0.032	0.83	0.96	21,536	Both	27005778
Total cholesterol in large LDL	Metabolites	Lipid	Penalised median	18	-0.008	0.039	0.83	0.96	21,552	Both	27005778
C-reactive protein	Metabolites	NA	Penalised median	27	-0.011	0.054	0.84	0.96	NA	Both	NA
Cholesterol esters in large HDL	Metabolites	Lipid	Simple median	10	0.020	0.098	0.84	0.96	19,273	Both	27005778
Total lipids in very large VLDL	Metabolites	Lipid	Weighted median	7	-0.028	0.139	0.84	0.96	19,273	Both	27005778
Phospholipids in large LDL	Metabolites	Lipid	Simple median	18	-0.015	0.079	0.85	0.96	21,550	Both	27005778
Cholesterol esters in medium LDL	Metabolites	Lipid	Weighted median	17	-0.007	0.042	0.86	0.96	19,273	Both	27005778
Butyrylcarnitine	Metabolites	Lipid	RE IVW	5	-0.042	0.223	0.86	0.96	7,796	Both	24816252
Carnitine	Metabolites	Lipid	Simple median	15	-0.221	1.274	0.86	0.96	7,797	Both	24816252
Transferrin Saturation	Risk factor	Metal	RE IVW	3	-0.007	0.036	0.87	0.96	23,986	Both	25352340
3-methyl-2-oxovalerate	Metabolites	Amino acid	RE IVW	3	0.775	4.126	0.87	0.96	7,779	Both	24816252
Apolipoprotein A-I	Metabolites	Protein	Penalised median	7	0.017	0.102	0.87	0.96	20,687	Both	27005778
X-12244--N-acetylcarnosine	Metabolites	Peptide	RE IVW	3	0.099	0.533	0.87	0.96	6,608	Both	24816252

Ferritin	Risk factor	Metal	RE IVW	4	0.016	0.094	0.88	0.96	23,986	Both	25352340
Glycoproteins	Metabolites	Protein	Simple median	7	0.018	0.119	0.88	0.96	18,734	Both	27005778
Total cholesterol in medium LDL	Metabolites	Lipid	Simple median	16	0.011	0.081	0.89	0.96	21,559	Both	27005778
Total lipids in medium LDL	Metabolites	Lipid	Simple median	16	0.011	0.085	0.89	0.96	19,273	Both	27005778
Concentration of medium LDL particles	Metabolites	Lipid	Simple median	14	0.012	0.090	0.90	0.96	19,273	Both	27005778
Cholesterol esters in medium HDL	Metabolites	Lipid	RE IVW	6	0.016	0.117	0.90	0.96	19,273	Both	27005778
Total lipids in large LDL	Metabolites	Lipid	Simple median	18	0.010	0.082	0.90	0.96	19,273	Both	27005778
Concentration of very large VLDL particles	Metabolites	Lipid	Penalised median	6	-0.017	0.141	0.90	0.96	18,960	Both	27005778
X-12850	Metabolites	Unknown metabolite	RE IVW	3	0.056	0.409	0.90	0.96	6,251	Both	24816252
Iron	Risk factor	Metal	RE IVW	3	-0.005	0.047	0.92	0.98	23,986	Both	25352340
Total cholesterol in small VLDL	Metabolites	Lipid	Penalised median	11	-0.006	0.055	0.92	0.98	21,557	Both	27005778
2-aminobutyrate	Metabolites	Amino acid	RE IVW	2	-0.142	1.259	0.93	0.98	7,814	Both	24816252
Phosphatidylcholine and other cholines	Metabolites	Lipid	RE IVW	4	-0.006	0.073	0.94	0.98	13,542	Both	27005778
Copper	Risk factor	Metal	RE IVW	2	0.007	0.073	0.94	0.98	2,603	Both	23720494
X-11787	Metabolites	Unknown metabolite	RE IVW	2	-0.047	0.574	0.95	0.98	7,811	Both	24816252
Mean diameter for VLDL particles	Metabolites	Lipid	Simple median	9	0.007	0.112	0.95	0.98	19,273	Both	27005778
Concentration of medium VLDL particles	Metabolites	Lipid	Weighted median	11	-0.007	0.115	0.95	0.98	19,273	Both	27005778
Total lipids in chylomicrons and largest VLDL particles	Metabolites	Lipid	Simple median	7	0.009	0.170	0.96	0.98	18,960	Both	27005778
X-13548	Metabolites	Unknown metabolite	RE IVW	2	-0.165	2.646	0.96	0.98	6,022	Both	24816252
2-hydroxyisobutyrate	Metabolites	Amino acid	RE IVW	3	-0.020	0.359	0.96	0.98	6,539	Both	24816252
Total cholesterol in medium HDL	Metabolites	Lipid	RE IVW	5	0.007	0.159	0.97	0.98	21,558	Both	27005778
Total cholesterol in large HDL	Metabolites	Lipid	Weighted mode	10	-0.003	0.085	0.97	0.98	21,558	Both	27005778
Concentration of IDL particles	Metabolites	Lipid	Simple median	15	-0.003	0.080	0.97	0.98	19,273	Both	27005778
Concentration of large LDL particles	Metabolites	Lipid	Simple median	19	-0.003	0.080	0.97	0.98	19,273	Both	27005778
Free cholesterol in very large HDL	Metabolites	Lipid	Simple median	15	-0.003	0.102	0.97	0.98	21,542	Both	27005778
Omega-3 fatty acids	Metabolites	Fatty acid	RE IVW	5	0.006	0.286	0.98	0.99	13,544	Both	27005778
Free cholesterol in medium HDL	Metabolites	Lipid	RE IVW	4	-0.003	0.174	0.99	0.99	21,559	Both	27005778